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Abstract 
 
Cancer immunotherapies aim to target the immune defence mechanisms of the body specifically and efficiently against the tumour 
tissue. Cancer vaccines and oncolytic viruses are forms of active immunotherapies, which require patients having a properly 
functioning immune system. The vaccines are based on the administration of tumour antigens into the body to which the immune 
system reacts. However, often the response is not robust enough. The oncolytic viruses in turn kill the cancer cells which causes the 
release of antigens from the tumour tissue. Viruses usually elicit a strong immune response but sometimes it is targeted too much 
against the virus instead of the tumour.  
 
Oncolytic vaccine is a composition of an oncolytic virus and a cancer vaccine. Tumour antigens can be coded to the genome of the 
virus therefore, when the virus invades tumour cells they start to produce the antigens. Eventually the cancer cells are also destroyed 
due to viral replication. The antigens can be tumour-associated that is, they are expressed in healthy tissues too. Their usage is not 
always efficient which is why an interest towards utilizing tumour-specific antigens has been increased. Considering the expression 
of antigens, tumour tissue is very heterogenous and distinctive between patients. Hence, utilizing mutated patient unique neoantigens 
would enable the development of personalized tumour-specific oncolytic vaccines. Genetic modification of viruses is complicated 
thus, an easier way to insert the neoantigens to the virus has been invented. The developed oncolytic vaccine platform is called 
PeptiENV, and it is designed to use with enveloped viruses. The idea is to fuse tumour-specific antigens onto the envelope of the 
virus and eliminate the need of gene insertion.  
 
The aim of this study is to investigate in vivo the efficacy of PeptiENV in preventing tumour growth and eliciting a tumour-specific 
immune response. An object is also to observe survival times of the treated animals. Furthermore, the preservation of infectivity is 
studied in vitro. The research was executed with two potential oncolytic viruses, vaccinia virus (VACV) and herpes simplex virus type 
1 (HSV-1). The PeptiENV complex was formed by using an artificial tumour antigen, ovalbumin epitope SIINFEKL, which was 
attached to the viral envelope with cell penetrating peptide (CPP) or cholesterol anchor. The preservation of infectivity was examined 
by measuring cell viability of PeptiENV infected cells. Animal experiments instead were performed with a mouse melanoma model 
created with B16-OVA cells, which express ovalbumin and therefore the antigen epitope SIINFEKL. PeptiENV was compared to 
control treatments which were virus, SIINFEKL peptide and complexation medium only. Treatments were administered as 
intratumoural injections. Tumour growth was followed by measuring the size of implanted tumours every other day. With flow 
cytometry, tumour-specific immune response was assessed by acquiring the relative amount of SIINFEKL-specific CD8+ T cells in 
the tumour tissue. Euthanizing dates were registered in order to observe the survival of the mice.  
 
According to the in vitro results, conjugation of peptides to the virus does not affect infectivity. In addition, the in vivo studies show 
that PeptiENV VACV CPP prevents tumour growth the most. Difference in tumour growth between PeptiENV VACV CPP and control 
treatments is significant. Mice injected with the same treatment also lived considerably longer than mice injected with virus, peptide 
or medium only. Also, PeptiENV HSV-1 hinders tumour growth distinctly more than virus only and slightly more than SIINFEKL only, 
but unfortunately it did not have an evident impact on the survival time. In both experiments, the PeptiENV treatment elicits the 
largest proportional amount of SIINFEKL-specific CD8+ T cells. In other words, PeptiENV engenders a tumour-specific immune 
response. In the PeptiENV VACV study the difference to control treatments is clearer than in the PeptiENV HSV-1 study.  
 
At present, the PeptiENV platforms performs better with VACV than HSV-1. With further investigations however, the results can be 
verified and improved. All in all, the results are encouraging. The PeptiENV platform shows great promise for being a part of 
personalized cancer immunotherapy developments in the future.   
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Tiivistelmä 
Syövän immunoterapian tavoitteena on kohdistaa kehon immuunipuolustusreaktio tehokkaasti ja tarkasti syöpäsoluja vastaan. 
Syöpärokotteet ja onkolyyttiset virukset ovat niin kutsuttuja aktiivisia immunoterapioita. Jotta potilas hyötyisi näistä hoidoista, 
immuunijärjestelmän täytyy toimia riittävästi. Syöpärokotteet perustuvat immuunijärjestelmän stimuloimiseen annostelemalla 
tuumoriantigeenejä potilaaseen. Hoidon aiheuttama immuunivaste ei kuitenkaan ole usein tarpeeksi voimakas. Onkolyyttiset virukset 
taas tuhoavat syöpäsoluja, minkä seurauksena tuumorikudoksesta vapautuu antigeenejä. Virukset saavat aikaan vahvan 
puolustusreaktion, mutta usein vaste muodostuu liikaa virusta vastaan syövän sijaan. Onkolyyttinen rokote on onkolyyttisen viruksen 
ja syöpärokotteen yhdistelmä. Tuumoriantigeenejä voidaan asentaa viruksen genomiin, jolloin viruksen infektoidessa syöpäsolun se 
alkaa tuottamaan kyseistä antigeeniä. Lopulta syöpäsolut myös tuhoutuvat johtuen viruksen replikoitumisesta. Koodatut antigeenit 
voivat olla tuumorispesifisiä tarkoittaen, että ne ilmentyvät ainoastaan syöpäsolujen pinnalla. On myös tuumoriantigeenejä, jotka 
voivat esiintyä samanaikaisesti sekä terveessä että pahanlaatuisessa kudoksessa. Tällaisten antigeenien käyttö ei ole aina 
tehokasta, minkä vuoksi kiinnostus tuumorispesifisiä antigeenejä kohtaan on lisääntynyt. Tuumorikudos on erittäin heterogeeninen, 
mikä johtuu syöpäsolujen jatkuvista mutaatioista. Tämän seurauksena syöpäsolujen pinnalla ilmennetään laajasti erilaisia 
antigeenejä, joiden vaihtelu potilaiden välillä on myös suurta. Mutatoituneiden potilasspesifisten neoantigeenien käyttö mahdollistaisi 
personoitujen tuumorispesifisten onkolyyttisten rokotteiden kehittämisen. Virusten geneettinen manipulaatio on kuitenkin 
monimutkaista, minkä vuoksi luotiin käytännöllisempi onkolyyttinen syöpärokotealusta PeptiENV, joka on suunniteltu vaipallisille 
viruksille. Ideana on kiinnittää tuumoriantigeenit suoraan viruksen vaippaan, jolloin geenien muokkaus ei ole tarpeellista.  
 
Tämän tutkimuksen tavoitteena on selvittää in vivo PeptiENV alustan tehokkuus tuumorikudoksen kasvun ehkäisyssä sekä 
tuumorispesifisen immuunivasteen tuottamisessa. Tarkoituksena on myös havainnoida PeptiENV alustan vaikutusta eläinten 
elossaoloaikaan. Lisäksi alustan infektiivisyyden säilyminen analysoidaan in vitro. Tutkimus toteutettiin käyttämällä kahta 
onkolyyttistä virusta, vaccinia virusta (VACV) sekä herpes simplex virus tyyppiä 1 (HSV-1). PeptiENV kompleksi muodostettiin 
kiinnittämällä ovalbumiinista peräisin oleva keinotekoinen antigeeniepitooppi SIINFEKL virusten vaippaan. Epitoopin liittämiseen 
käytettiin solukalvon läpäisevää peptidiä (cell penetrating peptide, CPP) tai kolesterolia. Infektiivisyyden säilyminen tutkittiin 
määrittämällä PeptiENV alustalla infektoitujen solujen kuolleisuus. Eläinkokeet taas suoritettiin hiirillä, joihin implantoitiin B16-OVA 
melanoomasoluja, jotka ilmentävät ovalbumiinia ja siten SIINFEKL-epitooppia. PeptiENV hoitoa verrattiin kontrolleihin, jotka olivat 
onkolyyttinen virus, peptidit ja kompleksaatioon käytetty liuos. Hoidot injektoitiin intratumoraalisesti. Tuumoreiden kasvua seurattiin 
mittaamalla tuumorien koko joka toinen päivä. Sen sijaan virtaussytometriaa käytettiin selvittämään SIINFEKL-spesifisten CD8+ T-
solujen suhteellinen osuus kaikista T soluista tuumoreissa. Hiirten eutanasiapäivämäärät tallennettiin elossaoloaikojen seurantaa 
varten. 
  
In vitro kokeen tulosten mukaan PeptiENV kompleksaatio ei vaikuta viruksen infektointikykyyn. In vivo tutkimukset puolestaan 
osoittavat, että PeptiENV VACV CPP estää tuumorien kasvua tehokkaimmin. Ero kasvussa PeptiENV VACV CPP:n ja 
kontrollihoitojen välillä on merkittävä. Samaa hoitoa saaneet hiiret myös elivät huomattavasti pidempään. Myös PeptiENV HSV-1 
hidastaa tuumorien kasvua selvästi enemmän kuin HSV-1 ja hieman enemmän kuin SIINFEKL-peptidi. Valitettavasti PeptiENV HSV-
1 ei kuitenkaan kasvattanut hiirten elossaoloaikaa merkittävästi. Molemmissa tutkimuksissa PeptiENV alustalla hoidetuissa 
tuumoreissa on suurin suhteellinen määrä SIINFEKL-spesifisiä CD8+ T-soluja. Toisin sanoen PeptiENV saa aikaan 
tuumorispesifisen immuunivasteen. PeptiENV VACV kokeessa ero kontrollihoitoihin on selkeämpi kuin PeptiENV HSV-1 kokeessa.  
 
Tällä hetkellä PeptiENV VACV näyttää toimivan paremmin kuin PeptiENV HSV-1. Jatkotutkimukset ovat joka tapauksessa 
tarpeellisia, sillä niiden avulla tuloksia pystytään vahvistamaan sekä parantamaan. Kaiken kaikkiaan tulokset ovat kuitenkin 
rohkaisevia. On mahdollista, että PeptiENV syöpärokotealusta on potentiaalinen osa tulevaisuuden yksilöllisten 
syöpäimmunoterapioiden kehitystä.  
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I LITERATURE REVIEW 
 
 
1 INTRODUCTION 
 
Cancer is a general term for various diseases that involve abnormal growth of cells which 
are able to spread into surrounding tissues in the body and generate metastasis (National 
Cancer Institute 2015). It occurs worldwide and has become one of the leading causes of 
death (WHO 2017). In 2015, cancer resulted in 8.8 million fatalities globally. Cancer 
develops when the normal circle of cell renewal is disturbed (Hanahan and Weinberg 
2000). Normally, old or damaged cells go through apoptosis and are replaced with new 
ones, but in cancer the normal cells have gone through genetic changes which causes their 
harmful proliferation. Often the growing cells form a solid tissue mass that is called a 
tumour (National Cancer Institute 2015). If the tumour has the ability to spread into other 
organs, it is cancerous or malignant.   
 
Surgery is a cancer treatment which is frequently used for removing malignant tumours 
mechanically (National Cancer Institute 2017). It is not always applicable since many 
times the cell mass is located so that it is impossible to reach, or the cancer has formed 
several metastases. Other well-known cancer treatments are radiation therapy and 
chemotherapy. Radiation therapy utilizes ionizing radiation to destroy the DNA in cancer 
cells (Baskar et al. 2012). Damaged DNA prevents the cells from growing and promotes 
cell death. The treatment can be used locally or systemically depending on the cancer 
type (National Cancer Institute 2017). In chemotherapy different drugs are used for 
killing the cancer cells and hindering tumour growth. It is given systemically and usually 
applied for cancers that grow rapidly.  
 
Although surgery, radiation therapy and chemotherapy are very common treatments of 
cancer, they have challenges. In many cases, it is impossible to extirpate the tissue 
completely with surgery, and sometimes healthy tissue has to be removed also (National 
Cancer Institute 2017). Radiation and chemotherapy always affect healthy cells too which 
can cause damage in normal tissue and hence various side effects.    
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To the side of conventional cancer treatments, other remedies have been developed. One 
of these is immunotherapy which aims to target the immune defence mechanism of the 
body towards cancer (Papaioannou et al. 2016). The fact that immune system can 
recognize and fight tumour growth, has been discovered already in the 19th century, but 
due to limited clinical efficiency, eagerness for immunotherapy was modest (Yang 2015). 
For the last few decades, increasing knowledge of anti-cancer immune responses has led 
to extensive research, and during recent years great progress has been achieved in the 
development of cancer immunotherapies (Yang 2015; Voena and Chiarle 2016). Several 
types are available nowadays, for example cancer vaccines and oncolytic viruses 
(Chiocca and Rabkin 2014; Butterfield 2015).  
 
The main goal and challenge in cancer immunotherapy is to induce a strong enough 
immune response that is targeting only the cancer tissue (Papaioannou et al. 2016).  
Guiding the immune system is complicated as such, but tumour tissue also has the ability 
to evade the immune defence mechanisms which creates an additional difficulty (Voena 
and Chiarle 2016). Via different mode of actions, the therapies attempt to achieve the best 
efficacy, tumour-specificity and overcome the immunosuppressive tumour 
microenvironment. Like the traditional cancer treatments, also various immunotherapies 
can be used together (Butterfield 2015). By availing treatments that fulfil each other, it is 
possible to obtain their best advantages.  
 
The objective of this literature review is to present the main points and limitations of 
cancer immunotherapies and clarify what kind of treatments are currently available. First, 
the interactions between cancer development and the immune system are illustrated, and 
later different treatments are scrutinized. The focus will be on cancer vaccines, oncolytic 
viruses and their combinations. In the end, a novel oncolytic cancer vaccine platform 
called PeptiENV is presented after which the thesis continues with experimental part.  
 
 
 
 
3 
 
2 IMMUNOLOGY AND CANCER 
 
2.1 The immune system 
 
The immune system is divided into two parts which are innate and adaptive immunity 
(Netea et al. 2011; Murphy 2012). People are born with the innate immunity, and it 
includes mechanic defences such as the skin and mucous, the complement cascade, and 
also certain white-blood-cells or leucocytes.  Macrophages, dendritic cells, neutrophils 
and natural killer (NK) cells are very important leucocytes in the innate immune response 
(Murphy 2012). Macrophages and neutrophils participate in inflammation reaction and 
inhibit, for instance, entrance of bacteria into the body. Dendritic cells, as well as 
macrophages, are also essential for the adaptive immunity because they present antigens 
to lymphocytes which is critical for their activity. NK cells kill tumour cells or virus-
infected cells without additional activation. They identify invaded host cells by 
recognizing their altered surface proteins. The innate immunity is also called non-specific 
immune system since the response is generic and does not change even if the same antigen 
comes across. Although, the reaction is fast and the first defence mechanism that 
pathogens have to encounter (Netea et al. 2011).  
 
The response of the adaptive immune system on the contrary is specific and can be either 
fast or slow, depending on whether the antigen has been fought against before (Netea et 
al. 2011; Murphy 2012). That is to say, the system can form a memory towards antigens 
which enables more efficient and faster immune response if the same antigens are 
confronted again. The adaptive immune system composes of leucocytes called 
lymphocytes, T cells and B cells. T cells transmit cell-mediated immune response while 
B cells are in charge of humoral or antibody-mediated immunity (Murphy 2012). 
 
2.1.1 Cell-mediated immune response 
 
When a naïve T cell encounters with an antigen for the first time it develops into an 
effector T cell (Yatim and Lakkis 2015). Several types of effector T cells exist but if 
coarsely categorized, they can be divided into four groups which are helper, cytotoxic 
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(killer), memory and regulatory T cells (Murphy 2012). Helper T cells are crucial for the 
whole adaptive immunity since their activation is needed for the function of cytotoxic T 
cells and B cells. Cytotoxic T cells are important for eliminating intracellular pathogens, 
especially viruses.  Regulatory T cells, on the other hand, suppress the activity of other 
lymphocytes and assist in controlling the immune response (Yatim and Lakkis 2015). 
Memory T cells, in turn, maintain an immunity that has evolved after a disease or 
vaccination. Helper and cytotoxic T cells express cluster of differentiation (CD) 4 and 8 
glycoproteins on their surfaces, and therefore they are often referred to as effector CD4+ 
and CD8+ T cells, respectively (Murphy 2012).  
 
In order that naïve CD4+ and CD8+ T cells are able to become mature, antigens have to 
be presented to them by other cells (Zhu and Chen 2009). The presentation happens with 
major histocompatibility complex (MHC) proteins on antigen presenting cells (APC), 
which are dendritic cells, macrophages and B cells (Zhu and Chen 2009; Murphy 2012; 
Yatim and Lakkis 2015). First, the antigen is taken into an APC and processed (Murphy 
2012). Then a small part of it, an antigen epitope, is complexed with an MHC protein and 
transported to the cell surface. There are two classes of MHC molecules: MHC class I 
molecules are found in most cells, whereas MHC class II proteins exist only in APCs. 
CD4+ T cells have T cell receptors (TCRs) that only recognize antigen epitopes that are 
presented with MHC class II proteins, while the TCRs on CD8+ T cells react to epitopes 
complexed with MHC class I molecules.     
 
The antigen presentation is not the only requirement for T cell activation, but additional 
stimulating signals are needed as well. (Zhu and Chen 2009; Murphy 2012). Along with 
TCRs, CD4+ and CD8+ T cells have CD28 and cytotoxic T lymphocyte antigen-4 
(CTLA-4) receptors on their cell surfaces, which bind to B7 proteins on APCs (Figure 1). 
The CD28-B7 pairing acts as a costimulating effect and is necessary for the activation of 
both CD4+ and CD8+ T cells (Zhu and Chen 2009). Instead, the interaction of CTLA-4 
and B7 operates as an immune checkpoint which inhibits the activating signals of above 
mentioned MHC I/II-TCR and CD28-B7 pairs and thus downregulates the immune 
response (Murphy 2012). CD4+ T cells are activated more easily than CD8+ T cells, 
which often demand further stimulation. The maturated effector CD4+ T cells provide 
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the stimulus by secreting cytokines that accelerate the proliferation and differentiation of 
the CD8+ T cells. Consequently, they gain their full capacity to kill, for example, 
cancerous and virus-infected cells.   
 
 
Figure 1. T cell activation. Antigen is presented to T cells on APCs as a complex with 
MHC proteins class I and II.  T cells recognize the complex with specific TCRs and 
become mature. The binding of CD28 receptor and B7 protein offers a costimulating 
signal that ensures the complete activation of the T cells. The interaction between CTLA-
4 and B7 will impede the activating signals and limit the T cell response. APC = antigen 
presenting cell; TCR = T cell receptor (Murphy 2012; picture adapted from Papaioannou 
et al. 2016)  
 
2.1.2 Antibody-mediated immune response 
 
In contrast to T cells, B cells are capable of recognizing antigens directly with their 
surface receptors (Murphy 2012). After the receptors have recognized and bound to an 
antigen, the antigen-receptor complex is taken into the cell by endocytosis after which the 
antigen epitope is presented on the cell surface with MHC class II protein. B cells also 
need additional stimulation from the CD4+ T cells in order to become completely 
functional. CD4+ T cells express CD40 ligand (CD40L), which interacts with CD40 
receptors on APCs. Binding of the CD40L to CD40 activates the B cells further. Thus, 
following the epitope presentation, the CD4+ T cells recognize the complex and by 
subsequent cytokine secretion and binding of the CD40 and CD40L, the B cells transform 
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into plasma cells that produce antibodies that resemble the surface receptors. Part of the 
antigen-stimulated B cells develop into memory cells.  
 
2.2 Cancer pathogenesis 
 
The proliferation of cells and programmed cell death is highly regulated by various genes. 
They affect multiple cell signalling pathways, and when performing correctly they 
maintain homeostasis of cells and tissue integrity (Hanahan and Weinberg 2000). 
Alterations in these genes endanger to increased risk of developing cancer. Normal genes 
that are in charge of cell division are called proto-oncogenes (Torry and Cooper 1991). If 
mutated, they have potential to become more dangerous oncogenes, which lead to the 
growth of malignant tumours if activated. The genome of cells also contains tumour 
suppressor genes and “healing” genes that hinder cell division and repair DNA damages, 
respectively (Hanahan and Weinberg 2000). Defects in these functions may cause cancer 
as well.  
 
In order that normal tissue cells can evolve into malignant cancer cells, they have to 
acquire capabilities that enable the development (Hanahan and Weinberg 2011). The 
acquisition happens when appropriate oncogenes becomes active and disturb the 
regulatory circuits within cells. For example, many tumour cells have the ability to 
produce their own growth signals and hence, stimulate their proliferation independently. 
Also, tumours are insensitive to anti-growth signals and they are able to evade apoptosis.  
Capacity to replicate countlessly, produce new blood vessels around the tissue, that is 
angiogenesis, and generate metastasis are included to the properties of cancer cells as 
well.  
 
One component that enables cancer cells to obtain above said capabilities is that the 
genome of tumour cells is highly instable (Hanahan and Weinberg 2011). The instability 
increases with every cell division, which spawn to the emergence of spontaneous 
mutations. The advantageous qualities obtained from the mutated genes are then inherited 
to the next subclone of cells which promotes their outgrowth further. The rate of 
spontaneous mutations also tends to elevate during tumour progression, which leads to 
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that more tumour growth supporting properties occur. The hyperproliferation and faster 
appearing mutations causes that tumours become genetically heterogeneous. That is to 
say, the physiology and morphology of cancer cells can be remarkably variant, and 
different subpopulations can even exist within the same tumour (Hanahan and Weinberg 
2000; Hanahan and Weinberg 2011). Furthermore, the expression of cell surface proteins 
varies greatly (Vinay et al. 2015).  
 
Another significant factor in tumour development and obtaining earlier mentioned 
abilities is inflammation (Hanahan and Weinberg 2011). In general, inflammation is an 
acute protective local reaction that helps to restore normal cell function in an infected or 
damaged area (Zamarron and Chen 2011).  However, many carcinogens such as tobacco 
smoke and UV-radiation cause chronic inflammation which has been linked with cancer 
progression (Aggarwal et al. 2009). Carcinogens can trigger certain inflammatory cell 
signalling pathways, which affect transcription and proliferation of cells. Various tumour-
associated genes are regulated by these pathways and they have been proved to be active 
in many types of tumours. Inflammation reaction is also essential in the later stages of 
tumour development since cancer cells can create inflammatory environment by 
themselves (Mantovani et al. 2008). For instance, they produce mediators that allure 
inflammatory leucocytes. Overall, the immune cells have several roles in carcinogenesis, 
and they are discussed in the following chapter (Zamarron and Chen 2011).  
 
2.3 Cancer and immune response 
 
As told, it demands many steps that normal cells can become cancerous, and most of the 
time the immune system notices abnormal cells and destroys them (Dunn et al. 2004b). 
Though, tumours possess qualities that make them able to evade the immune defence 
mechanisms (Vinay et al. 2015). Consequently, even correctly functioning immune 
system is not always able to prevent tumours to develop.  
 
The overall phenomenon, which includes the success and failure of the immune system 
protecting from cancer development is called cancer immunoediting (Dunn et al. 2004a).  
It is divided into three parts that are elimination (also called immunosurveillance), 
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equilibrium and escape. The elimination part is the one that usually averts tumour 
progression entirely. If the elimination does not work properly the tumour enters the 
equilibrium phase where the tumour is maintained or modified.  Variant cancer cells may 
obtain properties that allow the evasion of immune defence which leads to the escape part 
in which the tumour progresses into a clinically significant cancer.   
 
The elimination part starts when emerging tumour cells disrupt the local tissue and cause 
the production of pro-inflammatory molecules and chemokines (Dunn et al. 2004b). 
Leucocytes from the innate immune system such as macrophages, NK cells and dendritic 
cells becomes alerted by these signals and arrive to the site of the tumour.  By recognizing 
certain tumour-specific ligands and complexes, the leucocytes are activated and begin to 
secrete a cytokine called interferon-ɣ (IFN-ɣ) which amplifies the effects of the innate 
immunity and triggers processes that results in partial killing of the tumour cells. The 
destruction of the cancer cells liberates tumour antigens, which in turn activates the 
adaptive immunity.  Dendritic cells present the antigens to naïve CD4+ T cells in lymph 
nodes causing their maturation which is followed by the activation of CD8+ T cells.  
 
CD8+ T cells and CD4+ T cells are major anti-tumour lymphocytes, and by recognizing 
the tumour antigens, they are able to find the cancer cells, and eventually inhibit their 
growth or destroy them (Dunn et al. 2004b; Zamarron and Chen 2011). The suppression 
of tumours happens via different cytokines of which IFN-ɣ is the most significant and 
produced by both effector CD8+ and CD4+ T cells (Zamarron and Chen 2011). 
Additionally, effector CD8+ T cells secrete cancer cell killing cytotoxins such as 
granzymes and perforin (Mittal et al. 2014).  As mentioned earlier, cancer cells can be 
genetically very heterogenous which is why new tumour antigens occur constantly and 
therefore, the immune defence process has to be repeated multiple times so that all cancer 
cells can be eradicated (Dunn et al. 2004b; Hanahan and Weinberg 2011).   
 
If the elimination part fails and cancer cells are not killed completely, the tumour shifts 
into equilibrium state (Dunn et al. 2004b). In this state, the immune system constantly 
destroys cancer cells while new ones arise. The problem is that the new cells have 
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differently mutated genome and increased ability to resist the immune attack. Also, the 
tumour may become less immunogenic.    
 
There are many complex mechanisms behind the immune evasion. One significant part 
is that the tumour microenvironment is immunosuppressive (Vinay et al. 2015). By 
secreting cytokines, tumour cells are able to draw immunosuppressive lymphocytes into 
the microenvironment, for instance certain regulatory T cells. Normally, regulatory T 
cells are critical for the human physiology because they obviate other T cells reacting to 
self-antigens and thus creating autoimmunity (Zamarron and Chen 2011). However, 
considering tumour progression their activity is not wanted. Inflammation induced by the 
tumour also causes the presence of other suppressive immune cells (Vinay et al. 2015). 
Myeloid derived suppressor cells and modulated dendritic cells can decrease the 
immunity of T cells, whereas tumour associated macrophages produce tumour growth 
promoting cytokines such as interleukin 10 (IL-10) and transforming growth factor beta 
(Vinay et al. 2015; Yang 2015). Cancer cells and also non-cancerous cells in the 
microenvironment are able to secrete immune suppressive mediators too (Vinay et al. 
2015).  
 
Another way that tumours aid the evasion of immune defence is downregulating of 
antigen presenting pathways such as MHC class I (Vinay et al. 2015). Consequently, 
antigens are not presented properly on the cancer cell surface, and CD8+ T cells cannot 
recognize them. Additionally, most tumour cells are not able to express costimulatory 
molecules which are crucial for enabling the functions of effector CD4+ and CD8+ T 
cells. Instead, they can express protein ligands for the immune checkpoints that inhibit 
the activation of T cells. One of these proteins is programmed cell death ligand 1 (PD-
L1) which is a member of the B7 protein family (Becker et al. 2013). By binding to the 
PD-1 receptor of T cells, some key pathways in the T cell activation process are disrupted, 
and hence their proliferation, survival and cytokine production are impeded.  
 
The equilibrium phase can last even for years before any detectable cancer is developed 
(Dunn et al. 2004b). The tumour enters escape phase, in other words, begins to grow when 
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the genetic changes confer enough resistance against the immune defence system, and the 
evasion mechanisms overcome the elimination processes.       
 
3 IMMUNOTHERAPY OF CANCER 
 
Cancer immunotherapy includes different treatments that utilizes the immune defence 
mechanisms to battle cancer (Papaioannou et al. 2016). Significant leaps in the research 
have been made during the decade after 2010, and currently various immunotherapies 
exist in the market (Papaioannou et al. 2016; Voena and Chiarle 2016). The treatments 
are divided into passive and active immunotherapies (Papaioannou et al. 2016). Passive 
treatments are suitable for cancer patients who have insufficient immune responses 
against the disease. Different immune cells or molecules are stimulated ex vivo after 
which they are injected to the patient. Active treatments, conversely, are based on 
initiating the immune defence mechanisms inside the body which then requires that 
patient’s immune system works adequately. These therapies consist of various cancer 
vaccines, oncolytic viruses and immune checkpoint inhibitors, and they are discussed 
more detailed in the following chapters.  
 
Monoclonal antibodies (mAbs) that are targeted to specific tumour antigens and used to 
recruit immune cells to kill cancer cells is a form of passive immunotherapy (Papaioannou 
et al. 2016). Several kinds of these mAbs are available such as rituximab, which is used 
for treating Non-Hodgkin’s lymphoma. Adoptive cell transfer is also a passive 
immunotherapy in which patient’s own T cells are exploited (Voena and Chiarle 2016). 
Tumour infiltrated lymphocytes are collected from the tumour of which specific anti-
tumour T cells are expanded and re-administered unmodified back into the patient. 
Peripheral T cells can also be used. Before reinfusion, they are genetically armed either 
with TCRs or chimeric antigen receptors (CARs) that enable the T cells to recognize the 
tumour antigens specifically. The CAR T cell therapy has been more promising, and in 
2017, the first two CAR T cell therapies were approved by the U.S. Food and Drug 
Administration (FDA) (FDA 2017a; FDA 2017b). One is for treating children with acute 
lymphoblastic leukaemia, and the other is for adults with advanced B cell lymphomas. 
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Third form of passive immunotherapy is the use of cytokines, for instance, IL-2 and IFN-
α, which are both approved by the FDA (FDA 2012; Papaioannou et al. 2016).  
 
3.1 Immune checkpoint inhibitors  
 
In order that effector T cells gain their full function, the costimulating bindings discussed 
in chapter 2.1.1 need to happen (Murphy 2012).  As said, the T cells also express CTLA-
4 receptors, which interact with the B7 molecules too, and thus compete with the 
activating interaction of CD28 and B7 (Ito et al. 2015). The binding of CTLA-4 to B7 
averts naïve T cells from activating and operates as a “brake” for the immune response 
(Ito et al. 2015; Papaioannou et al. 2016). Another inhibitory surface protein on T cells is 
PD-1 (Ito et al. 2015).  It binds to PD-L1, which is expressed, inter alia, on tumour cells 
and also belongs to B7 protein ligands. The PD-1-PD-L1 complex works in the later 
stages of T cell activation and causes their exhaustion. The purpose of these hindering 
signals is to prevent autoimmunity and excessive tissue damage during infections, but 
they also induce immunosuppressive tumour microenvironment (Ito et al. 2015; Voena 
and Chiarle 2016). The anti-tumour T cell response can be boosted by blocking the 
inhibitory signalling with specifically targeted mAbs that are called immune checkpoint 
inhibitors (ICIs) (Papaioannou et al. 2016).  
 
The first ICI, ipilimumab, which binds directly to the CTLA-4 receptor and blocks the 
CTLA-4/B7 interaction, was approved by the FDA in 2011 for treating metastatic 
melanoma (FDA 2011; Ito et al. 2015). The approval was received after two prominent 
phase III studies (Hodi et al. 2010; Robert et al. 2011; Ito et al. 2015). Hodi (2010) and 
Robert (2011) with their research groups showed that ipilimumab, compared to melanoma 
vaccine and dacarbazine (chemotherapy medication), respectively, significantly 
prolonged the overall survival of patients with advanced melanoma. Another CTLA-4 
blocker in development is tremelimumab (Comin-Anduix et al. 2016). It has been in 
several clinical trials for treating cancer, but it has not yet been approved by the FDA.     
 
Two other ICIs for treating advanced melanoma, pembrolizumab and nivolumab, were 
approved by the FDA in 2014 (FDA 2014a; FDA 2014b; Papaioannou et al. 2016). Both 
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of them target the PD-1 receptor on T cells, but pembrolizumab with higher affinity 
(Papaioannou et al. 2016). By 2016, they were approved for several other indications too.  
 
Despite the successful outcomes, the inhibitors have limitations too. For instance, they 
cause immune-related adverse effects (irAEs) (Koster et al. 2015). Mild and moderate 
irAEs with ipilimumab occur in 60 % of patients, and the incidence for severe toxicities 
is 10–15 % (Hodi et al. 2010). Anti-PD-1 treatment also produces irAEs but not as much 
as blocking the CTLA-4 (Koster et al. 2015). Another major issue is that many patients 
do not or poorly respond to the treatment (Voena and Chiarle 2016; Ribas et al. 2017). 
Topalian et al. (2012) reported an objective response to anti-PD-1 therapy in 27 % of 
patients with melanoma, and only 19 % had a durable response longer than six months.  
As told, the ICI treatment is a form of active immunotherapy, and to function properly a 
T cell response against the tumour has to exist even at some extent (Obeid et al. 2015; 
Papaioannou et al. 2016).  Additionally, high immunogenicity of the tumour is noted to 
be advantageous, for example, by Snyder et al. (2014) and Rizvi et al. (2015) who 
detected that patients with highly mutated cancers responded to ICIs better. According to 
the studies, this could be derived from the emergence of new mutations, and thus, new 
tumour antigens to which the immune system reacts.    
 
To enhance the responses, CTLA-4 and PD-1 blockers have been also studied as a 
combination therapy, since they have different affecting mechanisms (Voena and Chiarle 
2016). CTLA-4 inhibitors increase tumour infiltrating lymphocytes, while PD-1 blockers 
help overcome immune evasion of the tumour (Sharma and Allison 2015). That is why 
the treatments can complement each other.  In addition to inadequate responses, another 
challenge has been the determination of biomarkers that would predict whether a patient 
will benefit from ICIs or not (Voena and Chiarle 2016).  Nonetheless, the discovery of 
the inhibitory signalling pathways and development of the checkpoint blockades have 
been one of the most remarkable advances in cancer immunotherapy (Ito et al. 2015; 
Voena and Chiarle 2016).   
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3.2 Cancer vaccines 
 
Cancer vaccines as treatments are also considered to be active immunotherapy 
(Papaioannou et al. 2016). The basic idea is to provoke anti-tumour immunity, especially 
specific cytotoxic CD8+ T cell response, by administrating tumour antigens into the body 
(Butterfield 2015). The antigens can be divided roughly into two classes: tumour-
associated (TAAs) and tumour-specific antigens (TSAs) (Buonaguro et al. 2011; Obeid 
et al. 2015). TAAs are expressed mostly in cancerous tissue, but they also occur in normal 
cells and are usually shared, that is, found in different patients’ tumours. TSAs can also 
be shared antigens, if the mutations are very typical to cancer cells. However, TSAs are 
often patient specific. In other words, they are conducted from distinctive mutations in 
the tumour and often referred to as neoantigens. They are expressed solely on cancer cells.  
 
3.2.1 Peptide-based vaccines 
 
Variable cancer vaccine platforms have been invented to operate as vehicles in delivering 
and presenting the tumour antigens to the immune system (Butterfield 2015; Obeid et al. 
2015; Papaioannou 2016). One method is to deliver antigens as peptides. Single or several 
kinds can be injected either alone or mixed with an adjuvant. The most frequently used 
approach is administering a certain antigen as a MHC class I restricted peptide, which is 
derived from TAAs (Butterfield 2015). These short epitopes, usually 8–11 amino acids 
in length, are either processed and presented by APCs or bound to the MHC I molecules 
directly on the surface of APCs (Butterfield 2015; Obeid et al. 2015).   
 
Problem is that these epitopes can only be used with patients who share common HLA 
haplotype of genes that express the MHC proteins (Butterfield 2015). Also, the epitopes 
do not stimulate the activation of important CD4+ T cells, which has been tried to achieve 
by making the peptides longer, approximately 20–45 amino acids in length, to involve 
epitopes for the CD4+ T cells (Butterfield 2015; Obeid et al. 2015). These peptides 
necessitate processing by APCs, but the antigen presentation is effective, and the epitopes 
are complexed with MHC class I and II molecules evoking the activation of both CD8+ 
and CD4+ T cells. For wider spectrum of MHC antigen peptides, full length tumour 
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antigen proteins have also been investigated. Even though, the use of longer peptides does 
not yet offer complete solution because it is more likely that also self-antigens are 
presented to the immune system which causes an increased risk for autoimmunity (Obeid 
et al. 2015).   
 
The peptide-based cancer vaccines have been studied in several clinical trials, and they 
have shown great promise (Aranda et al. 2013). Nevertheless, not one peptide vaccine 
has been approved by the FDA due to inadequate efficacy. One reason for this is most 
likely the issue that TAAs are expressed also in healthy tissues which may lead to immune 
tolerance and activation of regulatory T cells that suppress responses against self-antigens 
(Buonaguro et al. 2011; Zamarron and Chen 2011). Also, immune attack induced by 
delivering a single TAA might end up being insufficient since the spectrum of target 
antigens for the T cell response will be very narrow (Buonaguro et al. 2011). Furthermore, 
the immunosuppressive activities of the tumour cells, discussed in chapter 2.3, creates an 
additional hindrance.  
 
3.2.2 Whole cell-based vaccines 
  
Another means utilized for antigen delivery is the use of whole cells such as APCs or 
tumour cells (Butterfield 2015; Obeid et al. 2015; Papaioannou et al. 2016). The cells can 
be allogeneic or autologous that is, donated or patient’s own cells, respectively.  The most 
availed cells in whole cell vaccines are APCs, more precisely dendritic cells, because they 
have the ability to initiate and enhance immune responses (Butterfield 2015; Papaioannou 
et al. 2016). Two variant ways to exploit them have been established (Papaioannou et al. 
2016). With targeting vectors, antigens can be bound directly to the surface receptors of 
the dendritic cells in vivo which will lead to epitope presentation with MHC I and II 
proteins (Tacken et al. 2007; Papaioannou et al. 2016). Also, it is possible to stimulate 
the dendritic cell functions by administering the antigens with adjuvants (Obeid et al. 
2015). A more common approach is to load the cells with antigens ex vivo before infusion 
to the patient (Obeid et al. 2015; Papaioannou et al. 2016). 
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Dendritic cell-based vaccines possess many advantages; they are safe, achievable, and 
they can be loaded with many kinds of antigens and combined with range of adjuvants 
(Butterfield 2015; Papaioannou et al. 2016). Manufacturing can be however, arduous and 
expensive (Papaioannou et al. 2016) Even so, a dendritic cell-based vaccine sipuleucel-T 
is the first and so far, the only cancer vaccine approved by the FDA (FDA 2010; Melero 
et al. 2014). The approval was given in 2010 after a phase III clinical trial executed by 
Kantoff (2010) and his colleagues (FDA 2010). Sipuleucel-T elongated the survival of 
men with metastatic castration-resistant prostate cancer. The median survival was 4.1 
months longer in the treatment group than in the placebo group. The vaccine is prepared 
from autologous peripheral-blood mononuclear cells that include APCs. The dendritic 
cells are collected from the cell preparation by gradient centrifugation after which they 
are pulsed with a fusion protein that comprises of a TAA prostatic acid phosphatase and 
an immune cell activator (Kantoff et al. 2010; Butterfield 2015; Obeid et al. 2015).  
 
As mentioned, tumour cells have also been tested as cancer vaccine platforms. They offer 
a large repertoire of antigens which may contain such that are relevant for the immune 
response but cannot be identified (Obeid et al. 2015). This benefit could enable more 
efficient T cell response, although the chance of expressing self-antigens and eliciting 
autoimmunity might become greater.  
 
Both autologous and allogeneic tumour cells have been examined (Butterfield 2015; 
Obeid et al. 2015; Papaioannou et al. 2016). Autologous cells supply a spectrum of patient 
unique neoantigens, which could be beneficial in the development of personalized 
immunotherapy (Obeid et al. 2015; Papaioannou et al. 2016). Nevertheless, their 
manufacturing is demanding, and it is noticed that the allogeneic cells are more practical. 
They are a good source of TAAs, have better suitability for production, and variability 
between batches is small which allows comparing patients’ clinical outcomes 
(Papaioannou et al. 2016). To be more immunogenic, the allogeneic tumour cells are 
transfected to secrete certain cytokines and express costimulating molecules which is 
followed by inactivation with radiation to stop their proliferation. One potential 
application is modulating the cells to produce cytokine called granulocyte-macrophage 
colony stimulating factor (GM-CSF) (Butterfield 2015; Papaioannou et al. 2016). It 
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amplifies the actions of APCs and supports the presentation of the tumour antigens 
(Papaioannou et al. 2016).   
 
In addition to all vaccine platforms viewed, antigens can also be delivered as DNA or 
RNA that code the tumour antigens (Obeid et al. 2015). The genetic material is 
administered either as naked DNA or RNA or, for example, with a viral vector. The 
immune response is completely dependent on the antigen presentation by APCs, and 
sometimes the genes are edited so that they also contain stimulating factors such as the 
GM-CSF.  Viruses that destroy tumour cells, or oncolytic viruses, may also be considered 
as cancer vaccines because the demolition of the cells releases tumour antigens which 
leads to the activation of immune defence mechanisms (Obeid et al. 2015). Oncolytic 
viruses are discussed more thoroughly in the following section.  
 
3.3 Oncolytic viruses 
 
Virus is a biological organism that needs a host cell to proliferate (Murphy 2012). It 
invades the host cell and exploits it by forcing the cell to translate the genome of the virus 
and perform protein synthesis in order to produce new viral material. The genome, DNA 
or RNA, is also copied for new viruses. After this process called replication, the viruses 
abandon the cell leaving it damaged and ultimately dead and try to find new host cells in 
which to proliferate again. As a result, viruses can engender multiple hazardous diseases.  
 
Oncolytic viruses have a unique ability to selectively replicate in cancer cells and 
exterminate them without injuring healthy cells and being pathogenic (Chiocca and 
Rabkin 2014). Some viruses kill tumour cells specifically in their native form, but it is 
also possible to genetically modify them to do so (Kaufman et al. 2015). Furthermore, 
they can generate a systemic immune response against cancer which is fundamental for 
their clinical efficacy. Typically, the viruses are injected straight into tumour tissue in 
order to bypass physical barriers created by the tumour and its surroundings. Along with 
ICIs and vaccines, oncolytic viruses are a type of active cancer immunotherapy as well 
(Papaioannou et al. 2016).  
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The mechanisms behind the lytic activities and eliciting immune attack are not completely 
understood, yet several probable factors have been discovered (Kaufman et al. 2015). In 
healthy cells, where different cell signalling pathways are normal, viral eradication 
systems operate accordingly. On the contrary, as discussed in chapter 2.2, in cancer cells 
variable oncogenes are active and regulation of cell functions is impaired which enables 
efficient proliferation of the viruses in distinctive ways (Hanahan and Weinberg 2011; 
Kaufman et al. 2015). First of all, the division of cancer cells is rapid and consequently, 
protein synthesis is intensive (Kaufman et al. 2015). This provides a productive 
machinery for the virus to utilize for replication and building its own viral components. 
The capacity of tumour cells to avoid apoptosis also aids the proliferation because the 
cells will stay alive longer thus, the virus has a prolonged period of time available for 
replication. For the same reason, spreading of the virus is easier as well. Moreover, 
specific cell signalling pathways that are responsible in healthy cells for annihilating 
viruses are often malfunctioning in cancer cells. As a consequence, the amount of virus 
increases with time in the tumour unlike the dose of conventional drugs which makes 
the pharmacokinetics of oncolytic viruses extraordinary (Chiocca and Rabkin 2014).  
 
The actions mentioned above result eventually in the lysis of cancer cells, which 
subsequently releases TAAs and TSAs (Kaufman et al. 2015). The adaptive immune 
system responds to them and begins to reject the tumour. Because of the recognition, the 
immune cells are able to fight cancer cells that are not only at the viral infection site, but 
those as well that are located elsewhere and not affected by the virus. In addition to 
tumour antigens, the destroyed cells free pathogen- and danger-associated molecular 
pattern signals and cytokines that further the progress of APC maturation and full 
activation of CD4+ and CD8+ T cells, after which the CD8+ T cells migrate to established 
tumour growths.  
 
Beside the anti-tumour immunity, oncolytic viruses elicit anti-viral immune response, 
which is probably one of the most prominent limiting factors for oncolytic 
immunotherapy (Chiocca and Rabkin 2014). The defence mechanism composes of 
adaptive and innate immune responses, which both neutralize and clear the virus from the 
body. Depending on whether the virus has been recognized before by the immune system, 
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the immunity can be newly-formed or pre-existing, in which case the viral clearance can 
be very rapid (Kaufman et al. 2015). Regardless, if the anti-viral defence mechanism 
functions too dominantly, it can inhibit the tumour rejecting activities by eliminating the 
virus before it replicates fully and induces cytotoxic effects against the cancer cells 
(Chiocca and Rabkin 2014). Choosing to deliver the virus intratumourally may have a 
slight protective impact and is often more rational since intravenous dosing makes the 
virus even more exposed to the immune attack. Dosing directly into tumour is not 
unfortunately always possible, and intravenous injection is more pragmatic (Chiocca and 
Rabkin 2014; Breitbach et al. 2016).   
 
Determining the level of how much the anti-viral immunity hinders the anti-tumour 
effects is complicated but it is most likely influenced by the tumour microenvironment 
and the qualities of the virus (Kaufman et al. 2015). For instance, some viruses are capable 
of modifying the immunosuppressive tumour microenvironment to a direction that 
promotes cancer eradication. The central point is that the balance between the anti-tumour 
and anti-viral immunities may govern therapeutic outcomes which is why strengthening 
the anti-tumour immunity is vital (Chiocca and Rabkin 2014).  
 
Several oncolytic viruses have been discovered and their use as prospective cancer 
treatments has been researched in clinical trials (Kaufman et al. 2015).  Currently, the 
most significant viruses being tested among others are, for example, vaccinia virus and 
herpes simplex virus. Vaccinia virus has been proceeded until phase II and III studies 
while herpes simplex virus has already been approved by the FDA for the treatment of 
melanoma (FDA 2015; Kaufman et al. 2015; ClinicalTrials.gov 2018a). 
 
3.3.1 Vaccinia virus 
 
Vaccinia virus (VACV) belongs to the poxvirus family and was originally used for 
vaccination against smallpox (Kaufman et al. 2015). It is a large membrane covered virus 
that has a DNA genome consisting of circa 190 kilobase pairs (kbs) (Smith et al. 2002; 
Kaufman et al. 2015). Additionally, it has capacity for foreign DNA of 25 kbs which 
enables versatile editing of gene expression (Smith et al. 2013). The replication of the 
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virus happens in the cell cytosol reducing concerns about insertional mutagenesis 
(Kaufman et al. 2015).   
 
VACV also has natural tropism to cancer cells but still, some genetic modifications have 
been made in order to emphasize its tumour specificity (Kaufman et al. 2015). The virus 
has been for example, attenuated by deleting genes that are necessary for the viral 
replication in normal cells but not in cancer cells which hinders the pathogenic effects. 
Since being naturally immunosuppressive too, meaning that it has the ability to evade 
immune responses, its immune effects have been enhanced (Smith et al. 2013; Kaufman 
et al. 2015). For instance, costimulating B7 molecules and immune stimulating factors 
have been applied to the genome to magnify anti-tumour T cell responses (Kaufman et 
al. 2015). VACV has shown great promise and it has been examined in multiple clinical 
trials.  
 
Kaufman (2005) with his colleagues, executed a phase I clinical study for the first time 
with a recombinant VACV that expresses B7.1 molecule, or CD80, which binds to the 
CD28 causing an activating signal for the immune system. The aim was to evaluate 
immune effects, such as tumour regression and T cell responses. Twelve patients with 
metastatic melanoma participated in the trial, and once a month they were given 
intralesional injections of the substance for three months. Six patients were selected into 
the T cell analysis which showed that all six developed a response against specific 
melanoma antigens. The tumour regression was defined by using standard response 
evaluation criteria in solid tumours (RECIST), which tells the size progression of tumour 
lesions. One person withdrew from the study after the first injections, therefore eleven 
were able to be included to this evaluation. Two out of eleven showed indications of 
regression, and one patient experienced complete disappearance of several tumours.  
 
In a later study, performed by Heo et al. (2013), a preparation referred to as 
pexastimogene devacirepvec (JX-594 or Pexa-Vec) was used. It is a VACV genetically 
engineered with the stimulating cytokine GM-CSF that was brought up in section 3.2. 
Cancer selectivity is also improved by disrupting the functions of a viral thymidine kinase 
gene. The object of this clinical trial was to compare results, such as overall survival, 
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achieved with two different virus doses. Thirty subjects with advanced hepatocellular 
carcinoma were enrolled to the study and divided into two dose groups, high and low. 
Treatments were injected intratumourally on days 1, 15 and 29. Size progression was also 
used in this study to observe responses, and the results did not differ much between the 
treatments. Instead, the survival times varied considerably; median overall survivals in 
the high and low dose groups were 14.1 and 6.7 months, respectively. Because of the 
potential, JX-594 proceeded to larger clinical trials, and currently recruiting to a phase III 
study is ongoing (ClinicalTrials.gov 2018a).  
 
3.3.2 Herpes simplex virus type 1 
 
Herpes simplex virus type 1 (HSV-1), like VACV, is an enveloped virus with double 
stranded DNA (Kaufman et al. 2015). The size of the genome although is smaller, only 
152 kbp, and the replication happens in the nucleus instead of the cytosol. HSV-1 is a 
member of alphaherpesvirus family and a serious pathogen. Infection can lead to skin 
lesions such as blisters and ulcers (Välimaa et al. 2013). The lesions eventually heal but 
the virus will stay in the body as latent in the ganglia of peripheral neurons and cause new 
outbreaks when activated. If the virus spreads to central nervous system, the infection can 
be lethal. As VACV, HSV-1 have been genetically modified to decrease the pathogenic 
effects but also to improve its oncolytic properties (Kaufman et al. 2015).  
 
The most successful HSV-1-derived product is talimogene laherparepvec (T-VEC) which 
is the first oncolytic virus approved by the FDA (FDA 2015; Hamid et al. 2017).  Two 
viral gene deletions have been made in the T-VEC (Liu et al. 2003; Andtbacka et al. 
2015). Removal of neurovirulence factor gene (ICP34.5) attenuates the pathogenicity of 
HSV-1 efficiently since it is mostly responsible for the toxicity of the virus (Andtbacka 
et al. 2015). That is to say, deleting the gene ensures that the virus cannot grow within 
neurons or mediate latency (Kaufman et al. 2015). Simultaneously, tumour specificity is 
strengthened (Liu et al. 2003; Andtbacka et al. 2015). Another gene referred to as ICP47 
prevents infected cells to present antigens to CD8+ T cells hence, it has been removed to 
intensify the stimulation of the immune system (Liu et al. 2003). Furthermore, the gene 
in charge of the GM-CSF production has been inserted.  
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T-VEC was approved in 2015 with the official indication of “the local treatment of 
unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma 
recurrent after initial surgery” (FDA 2015). The approval was preceded a major, 
randomized, open-label phase III study that compared T-VEC treatment to GM-CSF only 
(Andtbacka et al. 2015). From screened patients, 436 were randomized to treatment 
groups in a ratio of two-to-one thus, 295 would receive T-VEC and 141 GM-CSF only. 
T-VEC was injected intratumourally, whereas GM-CSF was given subcutaneously.  
Primary endpoint was durable response rate (DRR), which was defined so that response 
should be detected within twelve months after starting the treatment and last continuously 
at least six months or longer. The DRR in the T-VEC group was 16.3 % which is 
significantly higher than in the GM-CSF group in which it was only 2.1 %. Response was 
observed not only in the injected, but also in the un-injected lesions which points that to 
some extent a systemic immune response was achieved too.   
 
After the approval, T-VEC has been examined in many clinical trials alone and in 
combination with different therapies (ClinicalTrials.gov 2018e). The ICIs, ipilimumab 
and pembrolizumab, are proven to enhance T cell responses and assist overcoming the 
immunosuppressive tumour microenvironment (Voena and Chiarle 2016). Hence, they 
have been studied together with T-VEC with expectations that combination therapy 
would be more efficient than monotherapy (Papaioannou et al. 2016; Puzanov et al. 2016; 
Ribas et al. 2017).  
 
In two different phase Ib, open-label, multicentre, non-randomized clinical trials, the 
safety and efficacy of T-VEC/ipilimumab and T-VEC/pembrolizumab combination 
therapies were investigated (Puzanov et al. 2016; Ribas et al. 2017). 19 and 21 patients 
with advanced melanoma enrolled to the studies, respectively. In the T-VEC/ipilimumab 
research, only 18 participated to the efficacy studies (Puzanov et al. 2016). In both trials, 
the patients received a dose of T-VEC and ICI once a week (Puzanov et al. 2016; Ribas 
et al. 2017). The treatments were started with T-VEC, and the ICI was combined to the 
therapy after 6 weeks from the first T-VEC dosing. The T-VEC was administered as 
intratumoural injections every other week, except the first two doses, which were 
administered in four-week intervals. Instead, the ICIs were infused systemically either 
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every two or three weeks. Treatments were continued until beforehand defined endpoints. 
Regarding safety, dose-limiting toxicities were not observed in either studies.  
 
The efficiency was assessed with immune-related response criteria (Puzanov et al. 2016; 
Ribas et al. 2017). The overall response rate in the T-VEC/ipilimumab research was 50 
% (9 patients) of which four (22 %) experienced complete response that is, total tumour 
disappearance, and five (28 %) had a partial response or tumour regression (Puzanov et 
al. 2016). From these subjects eight had a durable response lasting at least six months. 
Out of the 21 patients in the T-VEC/pembrolizumab study, 62 % (13 individuals) 
responded to the treatment and seven of them (33 %) had a complete response (Ribas et 
al. 2017). Significant perception was that responders had an increased amount of tumour 
infiltrated CD8+ T cells after the T-VEC injections compared to baseline which was most 
likely very beneficial for the subsequent pembrolizumab treatment.  
 
The outcomes of the study by Puzanov et al. (2016) were compared to earlier studies 
performed with T-VEC and ipilimumab alone, and the overall response rate achieved in 
their trial was higher than in the earlier studies. This indicates that the combination 
therapy seems to be more potent than monotherapy. Although, the number of patients was 
much smaller in their research than in the previous trials which is why the conclusion is 
only directional and has to be verified with results from larger ongoing clinical trials 
(ClinicalTrials.gov 2018b). The results by Ribas et al. (2017) also imply that using T-
VEC with ICI therapy is advantageous. To confirm the outcome of that study, a 
randomized phase III clinical trial is ongoing as well (ClinicalTrials.gov 2018d).  
Research of using T-VEC for treating other cancers than melanoma such as pancreatic 
and breast cancer has also been executed (ClinicalTrials.gov 2018e). 
 
3.4 Oncolytic vaccines 
 
All previously discussed immunotherapies consist of individual successes and potential 
treatments that are being intensively studied. As more information about the therapies 
have been found, their characteristic issues have emerged too. All of the main limitations 
are related to the functions of the immune system; the immune response is not strong 
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enough, or targeting the attack is problematic (Chiocca and Rabkin 2014; Obeid et al. 
2015; Papaioannou et al. 2016). In addition, the tumour microenvironment creates a 
remarkable challenge because of the immunosuppressive properties (Vinay et al. 2015). 
However, the treatments also have benefits and combining them is one method to 
overcome these issues. Different options and modifications have already been developed 
as presented earlier in this review. This section will focus on the concept of joining 
together the principles of cancer vaccines and oncolytic viruses.   
 
Their combination is often referred to as an oncolytic vaccine, in which the virus operates 
as a carrier of tumour antigens meanwhile it replicates in the cancer cells and exterminates 
them (Lichty et al. 2014). Typically, a TAA is coded to the genome of the oncolytic virus 
(Elsedawy and Russel 2013). When the virus infects tumour cells, the antigen will be 
expressed through protein translation. Via destruction, the produced antigens, and other 
TAAs and TSAs from the tumour cells are introduced to the immune system which will 
engage APCs, especially dendritic cells that will present the antigens to the adaptive 
immunity. The virus itself also aids the maturation of the dendritic cells. Furthermore, the 
tumour antigen expression from the viral genome helps the overall presentation to be 
prevalent over viral antigens. Consequently, a more extensive and specific T cell response 
towards the cancer may be inflicted.   
 
It has been noted that the advantage explained in the theory can be accomplished better 
by using the oncolytic vaccines in prime-boost compositions in which the immune system 
is first primed with a virus encoding a TAA and later boosted with a different virus 
expressing the same TAA (Breitbach et al. 2016). Encouraging results have been 
elucidated. By using murine models, Bridle (2010) and Pol (2014) with their research 
teams tested replicating vesicular stomatitis virus (VSV) and rhabdovirus Maraba, 
respectively, which were engineered with a melanoma associated antigen, dopachrome 
tautomerase. Both studies obtained similar results: the recombinant viruses alone did not 
prolong the survival of the mice or engender a specific anti-tumour effect. Moreover, in 
the study by Bridle et al. (2010), the immune response targeting the virus was very high. 
But, when the mice were first primed with a replication-deficient adenovirus encoding 
the same melanoma antigen and later boosted with the replicating viruses, the relative 
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amount of IFN-ɣ secreting tumour-specific CD8+ T cells was significantly increased in 
the tumour and blood (Bridle et al. 2010; Pol et al. 2014). These results suggest that using 
replicating viruses as priming or mono treatments is not very sufficient. According to Pol 
et al. (2014), this might derive from a strong anti-viral immune response against the 
extremely immunogenic viral antigens that need to be expressed for the replication of the 
virus.  
 
Maraba virus that encodes the human melanoma associated antigen MAGE-A3 has 
moved forward to a phase I/II clinical study in which recruiting patients is ongoing 
(ClinicalTrials.gov 2018c).  The purpose is to determine a maximum feasible dose of the 
oncolytic vaccine when given alone or as a boosting treatment. As a priming vaccine an 
adenovirus expressing the same MAGE-A3 is used. Efficacy of utilizing the two vaccines 
as a prime-boost treatment is also assessed by evaluating objective tumour response rate 
with the RECIST criteria.  
 
The limitation with this approach is that the viruses are expressing only one tumour 
antigen, when the fact is that tumours present a large repertoire of both TAAs and TSAs 
(Hanahan and Weinberg 2011; Woller et al. 2014). A method, which has been exploited 
in trying to circumvent this problem, is to code an entire antigen library to the viral 
genome (Woller et al. 2014). The idea is to take xenogenic DNA from a healthy tissue, 
which is corresponding to the treatable tumour tissue, and insert it into the genome of an 
oncolytic virus (Kottke et al. 2011; Woller 2014). Hence, the virus will express variable 
TAAs and also self-antigens and generate an immune response against them. But, because 
the “self-antigens” are from a foreign source they will not hinder the attack and also do 
not cause strong autoimmunity. 
 
3.4.1  Personalized oncolytic vaccines 
 
Nearly all immunotherapies presented in this review are exploiting TAAs in various 
manners. TAAs have advantages since they can occur in number of patients permitting 
broad applicability (Buonaguro et al. 2011; Obeid et al. 2015). Nevertheless, challenging 
is that TAAs do not necessarily elicit a robust and a specific anti-tumour immunity 
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because they are types of self-antigens against which the immune system does not attack 
so vigorously (Gubin et al. 2015; Patel et al. 2017). TSAs instead, are not as prone to 
immunological tolerance and they are more visible to the immune system. Therefore, 
exploiting them could enable developing treatments that are more sufficiently targeting 
only tumours (Woller et al. 2014).  Especially utilizing neoantigens of individual patients 
would be beneficial since cancer cells mutate constantly and thus, expressed tumour 
antigens can be very variant between different persons (Hanahan and Weinberg 2011).  
In addition, it has been noted that genetic changes that render missense mutations have 
the largest probability to be expressed and recognized by the immune system (Zhang et 
al. 2017). Targeting neoantigens also has lower risk for auto-immunity.  
 
Accordingly, developing of personalized oncolytic vaccines requires the identification of 
patient’s mutated TSAs, and methods which accomplished that were earlier cumbersome 
and hard (Gubin et al. 2015). Today, however, technologies have been improved which 
is why an interest towards neoantigen-based immunotherapies has been augmented. The 
antigens could be engineered to the DNA of an oncolytic virus as done with the TAAs. 
Genetic modifications, on the other hand, are complex and do not suit for all viruses 
(Elsedawy and Russel 2013). A large genome allows gene insertions but in turn, those 
viruses also have very immunogenic epitopes which can lead to viral antigen epitope 
dominance. Second, performing various genetic manipulations is time-consuming, and 
every new alteration demands a re-evaluation by the authorities FDA and European 
Medicines Agency (Capasso et al. 2016).   
 
An effort to bring together the benefits of oncolytic vaccines and TSAs, and to eliminate 
the complexity of genetic modifications has been made by Capasso (2016) and his 
colleagues. They created an oncolytic vaccine platform called PeptiCRAd in which MHC 
class I restricted TSA epitopes are attached with electrostatic interactions directly onto 
the capsid of an adenovirus while leaving out unnecessary manipulations of the genome. 
The ability of the platform to hinder tumour growth and elicit a tumour specific immune 
response was studied by performing an animal experiment with a mouse melanoma 
model. The mice were implanted with melanoma cells (B16) that express an artificial 
TSA epitope referred to as SIINFEKL, which is derived from chicken ovalbumin. Hence, 
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the tested treatments were PeptiCRAd (formed by adsorbing the SIINFEKL peptide to 
the adenovirus), adenovirus mixed with SIINFEKL, virus only, peptide epitope only and 
injection medium (mock). The mice were treated three times on days 0, 2 and 7 by 
intratumoural injections. The results showed that PeptiCRAd significantly slows tumour 
growth, and in the end of the experiment the volume of the tumours in the PeptiCRAd 
treatment group were clearly smaller than in the control groups. Since adenovirus does 
not replicate in murine cells, the efficacy of PeptiCRAd engendered mainly via specific 
anti-tumour immune response. The relative amount of SIINFEKL targeted CD8+ T cells 
in the tumour, spleen and draining lymph nodes was significantly larger compared to the 
control treatments.    
 
3.4.2 PeptiENV platform 
 
The interest towards personalized immunotherapies and the promising results presented 
above encouraged to research whether the same idea would work with enveloped 
oncolytic viruses such as the VACV and the HSV-1, which have been pointed to be highly 
potential as cancer immunotherapies. Thus, a novel cancer vaccine platform called 
PeptiENV was developed (Figure 2).  
 
The principle, as in PeptiCRAd, is to attach MHC class I restricted tumour antigens onto 
the virus and therefore, stimulate a specific anti-tumour immune response especially 
through activating CD8+ T cells to target cancer cells. At first, how the tumour peptide 
epitopes to be attached would bind to the envelope was examined.  The peptide cannot be 
joined to the membrane as such, but instead, requires an additional link that operates as 
an anchor between the peptide and the envelope.  
27 
 
 
Figure 2. The structure of PeptiENV platform. The antigen epitope is linked to an anchor 
that attaches the epitope onto the envelope of the oncolytic virus (Ylösmäki et al. 
submitted).  
 
Several options were screened, and the outcomes pointed that the most secure way is to 
fix the peptide to either cell penetrating peptide (CPP) or to cholesterol (chol) (Ylösmäki 
et al. submitted). The anchors were fused to the same chicken derived TSA as in the study 
by Capasso et al. (2016), or SIINFEKL, and attached to the membranes of the VACV and 
HSV-1. The interactions between the CPP- and chol-SIINFEKL peptides and the 
envelopes of both viruses were studied, and they have been proved to be stable (Ylösmäki 
et al. submitted). If the platform would demonstrate to be efficient in later experiments, 
it could be utilized as a personalized cancer immunotherapy by attaching neoantigens of 
individual patients onto the viral envelope. 
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II EXPERIMENTAL PART 
 
 
4 AIM OF THE STUDY 
 
The aim of this study is to learn if PeptiENV treatment in vivo prevents tumour growth 
and generates a tumour antigen-specific T cell response more effectively than control 
treatments, especially an oncolytic virus only. Furthermore, the elongation of survival 
and the preservation of infectivity of the PeptiENV platform are investigated in vivo and 
in vitro, respectively. The research is executed with replicating VACV and HSV-1 thus, 
an objective is also to detect possible differences between the viruses and discuss them.  
 
The VACV is studied with SIINFEKL epitopes that are conjugated onto the viral 
envelope either with the CPP or the cholesterol anchor.  Instead, the HSV-1 is fused with 
SIINFEKL by using only CPP.  The infectivity of the PeptiENV platform is tested with 
cell viability assay. Tumour growth instead is examined with laboratory mice by using a 
murine skin cancer model created with mouse melanoma cells (B16) expressing the 
artificial tumour antigen SIINFEKL derived from chicken ovalbumin (OVA) that is, B16-
OVA cell line. Tumour-specific immune response is assessed by measuring the relative 
amount of SIINFEKL-specific CD8+ T cells in the tumour tissue with flow cytometry.  
 
 
5 MATERIALS AND METHODS 
 
5.1 Viruses and peptides 
 
The VACV used in the experiments (VACVdd-tdTomato-mDAI) is a genetically 
engineered Western Reserve strain of vaccinia virus provided by the 
ImmunoViroTherapyLab. The virus has double deletion (dd) in order to enhance cancer 
specific replication: one in the thymidine kinase gene and one in the vaccinia growth 
factor gene (Hirvinen et al. 2016).  Also, it is armed with a murine DNA-dependent 
activator of IFN-regulatory factors (mDAI) which is a sensor of cytosolic double-stranded 
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DNA. When stimulated, it activates the innate immune responses hence, it improves the 
immunogenicity of VACV. Furthermore, a red fluorescent protein (tdTomato) has been 
inserted.  
 
The HSV-1 used in the experiments (HSV-1 (17+) Lox-Luc) was a kind gift from Prof. 
Veijo Hukkanen (University of Turku, Finland). The virus is derived from the laboratory 
strain HSV-1(17+) and is also genetically modified: the firefly luciferase gene has been 
inserted (Nygårdas et al. 2013).  Suppliers of peptides and full amino acid sequences are 
found in Table 1.  
 
Table 1. Amino acid sequences and suppliers of the peptides used in the experiments. 
CPP = cell penetrating peptide 
Peptide Amino acid sequence Supplier 
CPP-SIINFEKL GRKKRRQRRRPQRWEKI-
SIINFEKL 
Ontores (China) 
chol-SIINFEKL 
 
cholesterol-C-SIINFEKL Pepscan (The Netherlands) 
 
5.2 Cell lines 
 
Murine melanoma cell line B16-OVA was cultured in Roswell Park Memorial Institute 
(RPMI) 1640 low glucose medium completed with 10 % fetal bovine serum (FBS), 1 % 
penicillin-streptomycin and 1 % L-glutamin (GlutaMAX™). Geneticin™ was added to 
B16-OVA culture flasks with concentration of 5 %. Murine triple negative breast cancer 
cell line 4T1 was cultured in RPMI 1640 high glucose medium supplemented with 10 % 
FBS and 1 % penicillin-streptomycin. Human lung cancer cell line A549 and human triple 
negative breast cancer cell line MDMBA436 were cultured in Dulbecco's modified Eagle 
medium (DMEM) completed with 10 % FBS and 1 % penicillin/streptomycin. All cell 
lines were grown in an incubator at temperature 37°C and 5 % of CO2. When subcultured, 
cells were washed with phosphate buffered saline (PBS) and detached with TrypLE™ 
enzyme solution. B16-OVA cell line was provided by Prof. Richard Vile (Mayo Clinic, 
Rochester, MN, USA). Other cell lines were acquired from ATCC (USA). All cell culture 
materials were ordered from Gibco® Life Technologies except DMEM, which was 
purchased from Lonza®. 
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5.3 Production of PeptiENV 
 
The PeptiENV complex was always produced right before experiments. It is formed by 
mixing a virus and a peptide in a certain volume of medium. In this study, the medium 
used was plain RPMI 1640. First, the medium is placed into a microcentrifuge tube. Next, 
the peptide is added to the tube and finally the virus. Then, the mix is kept at 37°C for 20-
30 minutes after which it is put in ice. All different complexes are formed individually in 
separate microcentrifuge tubes.  
 
Viruses and peptides are always mixed in a known ratio; in experiments performed in this 
study, 106 pfu (plaque forming units) of viruses were combined with 3.1 nmol of peptides. 
Although, the number of viruses and peptides varied between experiments, the ratio was 
constantly kept the same. 
 
5.4 Cell viability assay  
 
The preservation of infectivity of the PeptiENV platform was tested to prove that 
complexation of virus and peptide does not affect the infectivity of the virus. The 
experiment was performed with cell viability assay in which the used PeptiENV complex 
was formed with vaccinia virus and CPP-SIINFEKL. Cell viability after infecting with 
PeptiENV, was compared to infections with naked VACV, CPP-SIINFEKL only and 
complex formation medium (RPMI 1640). Complexation of PeptiENV was done as 
described earlier.  
 
Four different cell lines, B16-OVA, A549, 4T1 and MDMBA436, were utilized in the 
experiment. All cells were plated one day before infection in 96-well plates with density 
of 50 000 cells/well. The next day, the cells were infected by using four different 
concentrations of PeptiENV and each control treatment. Concentrations were determined 
as multiplicity of infection (MOI) which tells the relative amount of virus compared to 
number of cells. Strongest concentration used was MOI 1, that is, 50 000 viruses was 
used for infecting 50 000 cells. Lower concentrations were MOI 0.1, MOI 0.01 and MOI 
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0.001. Four repetitions of each concentration were made with every treatment to calculate 
means from the raw data. Demonstrative plate layout is shown in Figure 3.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 1 1 1 1 1 1 1 1 1 1 1 
B 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
C 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
D 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
E mock mock mock mock         
F mock mock mock mock         
G mock mock mock mock         
H mock mock mock mock         
Figure 3. Scheme of a 96-well plate in the cell viability assay. Cells were infected with 
different treatments and MOI concentrations (numbers). The same layout was used with 
all cell lines. Blue = PeptiENV; pink = vaccinia virus only; green = CPP-SIINFEKL 
peptide only; orange (mock) = medium only  
 
After infection, cells were kept in an incubator at temperature 37°C and 5 % of CO2 for 
three days, and cytopathic effects were checked daily. Cell viability was assessed by using 
CellTiter-Fluor™ Cell Viability Assay kit from Promega, which exploits protease activity 
within live cells (Promega.com). Live cells produce a fluorescent signal which was used 
to indicate the relative number of viable cells. Fluorescence of the cells was measured 
with Varioskan Lux (Thermo Scientific).    
 
5.5 Animal experiments 
 
Animal experiments were carried out by using laboratory mice. The strain of the mice 
was C57BL/6JOlaHsd and gender female. Mice were ordered from a commercial breeder 
Envigo (The Netherlands) at the age of 4–6 weeks. Animals were kept in individually 
ventilated cages in groups of 3‒5 mice. Food and water was provided all times, and cages 
were changed into clean ones once a week. Light time was 12 hours, from 6:00 to 18:00. 
All animal experiments were performed according to the Finnish Act (497/2013) and 
Government Decree (564/2013) on the protection of animals used for scientific or 
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educational purposes, and Directive (2010/63/EU) of the European Parliament and of the 
Council on the protection of animals used for scientific purposes. License for animal 
experiments has been authorized by the national Animal Experiment Board (ELLA, 
Eläinkoelautakunta).  
 
5.5.1 Tumour implantation 
 
The animal experiments were started with tumour implantation. B16-OVA cells were 
detached from culture flasks by using TrypLE™ Express (Gibco® Life Technologies) 
and collected into a sterile falcon tube. In the tube, cells were washed two times with 
PBS. Centrifugation speed was 400 x g and temperature 23°C (Allegra® X15R 
Centrifuge, Beckman Coulter). After second wash, the cell pellet was resuspended into 
plain RPMI 1640 medium. The aim was to implant 300 000 tumour cells into every mouse 
hence, the cells were counted, and concentration was adjusted to 6x106 cells/ml. Each 
mouse was injected with 50 µl of the cell suspension subcutaneously into the right flank. 
Mice were held under inhalational anaesthesia with 3 % isoflurane during injections. 
Following the implantation, mice were checked for growing tumours every other day and 
treatments were started when the tumour diameter reached approximately 4–5 mm (or 
volume 50 mm3). The mice that had not developed sufficient tumours were excluded from 
experiments. Animals that were included were randomized into different treatment 
groups. 
 
5.5.2 PeptiENV with vaccinia virus 
 
The first PeptiENV experiment was executed with VACV, CPP and cholesterol 
conjugated SIINFEKL peptides. Treatment and control groups are presented in Table 2. 
Tumours were grown enough after 11 days post implantation thus the treatments were 
started on that day. The treatments were prepared right before they were injected. The 
PeptiENV complexes were produced as described in chapter 5.3, and the amount of 
VACV used for one mouse was 106 pfu and therefore peptide amount was 3.1 nmol. The 
control treatments were also formed according to the PeptiENV production protocol but 
only virus or peptide were added to the medium containing tubes. The same amount of 
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virus and peptides as in PeptiENV were used in the VACV only group, and the CPP- and 
chol-SIINFEKL only groups. Substances were injected intratumourally in volume of 50 
µl, and inhalational anaesthesia with 3 % isoflurane was used during all injections. Over 
all, the mice were treated three times of which the first two were given in the beginning 
on days 11 and 13. The third injection was administered later as boosting treatment on 
day 19.  
 
Table 2. Treatment and control groups used in the PeptiENV VACV experiment. 
PeptiENV VACV CPP (vaccinia virus conjugated with CPP-SIINFEKL) and PeptiENV 
VACV chol (vaccinia virus conjugated with chol-SIINFEKL) were the studied 
treatments. VACV (vaccinia virus only) CPP-SIINFEKL (peptide only), chol-SIINFEKL 
(peptide only) and mock (injection/complexation medium only) were used as controls.  
Group Number of mice 
PeptiENV VACV CPP 7 
PeptiENV VACV chol 7 
VACV 7 
CPP-SIINFEKL 6 
chol-SIINFEKL 6 
Mock  7 
 
 
Tumour growth was followed by measuring the diameter of the tumours with a calliper 
every other day. Because the tumours are not completely symmetrical, the diameters were 
measured from two points, the narrowest and the widest part.  Measurements were started 
the same day as the treatments, and they were always performed before injections. As 
well as the treatments, measurements were also executed while the mice were under 
anaesthesia. Inhalational anaesthesia with 3 % isoflurane was used. To reduce stress and 
pain in the animals, the endpoint to the experiment was defined so that maximum tumour 
diameter allowed was 17 mm. When that diameter was reached or if the mice seemed 
unwell they were euthanized. Euthanizing dates were marked in order that survival times 
could be observed.  
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5.5.3 PeptiENV with herpes simplex virus type 1 
 
The basic principle of the second animal experiment was similar to the first one except, 
HSV-1 was used. Also, the results from the first experiment indicated that virus 
conjugated with chol-SIINFEKL does not have as effective outcome as the complex with 
CPP-SIINFEKL which is why HSV-1 was fused only with the CPP-SIINFEKL (Figure 
5). These results are presented later. The treatment and control groups are shown in Table 
3. 
 
Table 3. Treatment and control groups used in the PeptiENV HSV-1 experiment. 
PeptiENV HSV-1 CPP (herpes simplex virus type 1 conjugated with CPP-SIINFEKL 
peptide) was the studied treatment. HSV-1 (virus only), CPP-SIINFEKL (peptide only) 
and mock (injection/complexation medium) were used as controls.  
Group Number of mice 
PeptiENV HSV-1 CPP 8 
HSV-1  8 
CPP-SIINFEKL  5 
Mock 6 
 
Virus amount was increased from 106 pfu to 5 x 106 pfu per mouse and thus, peptide 
amount from 3.1 nmol to 15.5 nmol. Substances were injected intratumourally in volume 
of 50 µl.  Injections and measurements were started on day 10 when the tumours were 
large enough. In this experiment mice were treated also three times. The second 
treatments were injected on day 12 and third injections were administered on day 20 as 
boosting treatments. Measurements were continued every other day until previously 
described endpoint.  
 
5.5.4 Tissue collecting 
 
In both animal experiments, after euthanizing the mice, certain tissues were collected in 
order to perform immunological analysis of them later. The collected tissues were spleen, 
tumour draining lymph node and the tumour. Tissues were put in complete RPMI 1640 
medium and in ice after which they were immediately transferred for processing. By using 
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cell strainers, all organs were individually isolated into single-cell suspensions. Dimethyl 
sulfoxide (DMSO), obtained from Sigma-Aldrich, was added to the suspensions so that 
DMSO concentration was 10 %. Then, the suspensions were aliquoted into cryogenic 
vials and stored in – 80 °C.  
 
5.6 Immunological analysis 
 
Extracellular staining and flow cytometry were used to determine the relative amounts of 
SIINFEKL-specific CD8+ T cells in the tumours collected from the PeptiENV VACV 
and PeptiENV HSV-1 animal experiments. Also, the relative amount of VACV-specific 
CD8+ T cells was obtained from PeptiENV VACV study. Samples were taken from three 
different mice from each treatment and control group. Due to weaker results, PeptiENV 
VACV chol and thus chol-SIINFEKL only treatment groups were excluded from the 
analysis (Figure 5). Mice included to the analysis were chosen so that euthanizing dates 
were as close to each other as possible to reduce variability in the results.  
 
As soon as the samples were melted, they were placed into a 96-well plate and washed 
once with PBS. Fc receptors, which occur in the surface of many immune cells and bind 
several kinds of antibodies, were blocked by using TruStain fcXTM to eliminate false 
positive results. After, the samples were protected from light throughout the protocol. 
Samples were also pooled together according to treatment groups. Incubation time with 
the Fc block was 15 minutes and temperature 4°C. Following the incubation, fluorophore-
conjugated pentamers were put to the pooled samples. APC labelled SIINFEKL was used 
in both PeptiENV VACV and HSV-1 analysis to detect SIINFEKL-specific CD8+ T 
cells. Instead, PE labelled VACV pentamer was used only in the PeptiENV VACV study 
to find VACV-specific CD8+ T cells. Pentamers were incubated 30 minutes at 23°C. 
Next, the samples were washed two times with PBS.  
 
In order to exclude B cells from the results and detect all T cells, fluorophore-conjugated 
antibodies were placed to the samples. The antibody used to find B cells was anti-CD19-
PeCy7, whereas anti-CD3-PerCpCy5.5 and anti-CD8-FITC were used to discover all T 
cells and CD8+ T cells, respectively. The antibodies were added as a mixture, and then 
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the samples were incubated for 30 minutes at 4°C. After the staining, cells were washed 
with PBS and fixed with 4 % Formalin (Sigma-Aldrich) followed by one additional wash 
and resuspension with PBS. Finally, the samples were transferred through cell strainer 
caps to tubes that are applicable for flow cytometry. Samples were analysed with Gallios 
Flow cytometer (Beckman Coulter).  
 
SIINFEKL pentamer (APC labelled Pro5 MHC I Pentamer, H-2Kb SIINFEKL), VACV 
pentamer (R-PE labelled Pro5 Pentamer, H-2Kb TSYKFESV) and CD8-FITC (rat 
isotype) antibody were purchased from Proimmune®.  Instead, Fc block (TruStain 
fcXTM, anti-mouse CD16/32) and antibodies CD19-PeCy7 (rat isotype) and CD3-
PerCpCy5.5 (hamster isotype) were supplied by BioLegend®.  
 
5.7 Data processing  
 
Raw data from the experiments was processed with different software programs. In 
animal experiments Microsoft Excel (2016) was used for calculating relative tumour 
volumes for each mouse from the measured diameters. Tumour volume growth 
percentages were obtained by comparing absolute volumes to the original volumes 
measured on the first treatment day. Averages for these values, standard deviations and 
growth curves were formed with GraphPad Prism 7 (GraphPad Software, Inc. La Jolla, 
CA, USA).  Microsoft Excel and GraphPad Prism were also used in data analysis in the 
cell viability assay. Means and standard deviations were calculated. Data from flow 
cytometry was analysed with FlowJo Software (Tree Star, Ashland, OR, USA). Results 
were transferred to GraphPad Prism 7 which was used for creating graphs and calculating 
averages and standard deviations. Additionally, statistics of the PeptiENV VACV 
immunological analysis were tested with one-way analysis of variance (one-way 
ANOVA).   
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6 RESULTS 
 
6.1 Cell viability assay 
 
The outcomes of the in vitro cell viability assay, which was executed to study the 
preservation of infectivity of PeptiENV, are presented in Figures 4A–4D. They show that 
the ability of infecting cells does not decrease when VACV is conjugated with CPP-
SIINFEKL. The viability of cells, when infected with PeptiENV or VACV only, does not 
differ significantly from each other. In addition, the Figures 4A–4D point that treating the 
cells with CPP-SIINFEKL only, does not affect viability more than treating with medium 
only.    
 
 
Figure 4. The viability of different cells (A–D), when they are treated with variable 
concentrations of PeptiENV, VACV only, CPP-SIINFEKL peptide only and medium 
only. Viability is presented as percentage, and in each graph cell viability is compared to 
uninfected cells (treated with medium) in which the viability is set to be 100 %. On the 
x-axis are shown different MOI (multiplicity of infection) concentrations. The values of 
the columns are averages and shown with standard deviations. PE = PeptiENV; VACV = 
vaccinia virus only; CPP = CPP-SIINFEKL peptide only; uninfected = medium only 
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6.2  Animal experiments: tumour growth and survival 
 
Tumour volume data was obtained to investigate tumour growth in PeptiENV VACV and 
HSV-1 animal experiments. Also, survival time was researched by collecting the 
euthanizing dates of the treated mice from both studies.  
 
6.2.1 PeptiENV with vaccinia virus 
 
Tumour growth curves from the PeptiENV VACV study are presented in Figure 5. They 
show that tumours treated with PeptiENV VACV CPP grow considerably slower than 
tumours that are injected with control substances.  
 
 
Figure 5. Tumour growth in different treatment groups in the PeptiENV VACV animal 
experiment. Sizes of the tumours were measured every other day and they are presented 
as average relative volumes (%) with standard deviations.  
 
With PeptiENV VACV CPP tumours expanded on average only three-fold until day 23. 
The second-best treatments after PeptiENV VACV CPP is PeptiENV VACV chol and 
VACV only. Those treatments delay tumour growth to some extent, but still, on day 23 
the mean volumes are 7 and 9 times larger than on day 11, respectively. Tumours treated 
with injection medium, CPP-SIINFEKL and chol-SIINFEKL only grow the fastest. On 
day 21, mean tumour volumes in the peptide only groups are 21 times larger than in the 
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beginning (day 11) while tumours injected with medium are on average 17 times bigger 
on day 23 compared to the start. 
 
Also, the survival curves in Figure 6 and 7 indicate that PeptiENV VACV CPP is the best 
treatment because majority of the mice in that treatment group stayed alive the longest, 
until day 45. Mice injected with PeptiENV VACV chol were mostly sacrificed until day 
35. Animals treated with chol- and CPP-SIINFEKL only were euthanized already on days 
27 and 33, respectively. There is no difference in survival times between the virus only 
treatment and mock. In both groups all mice were sacrificed until day 35. 
 
 
Figure 6. Survival percentages of different treatment groups in PeptiENV VACV 
experiment presented as Kaplan-Meier curve.  
 
 
Figure 7. Survival percentages of different treatment groups in PeptiENV VACV 
experiment presented as Kaplan-Meier curve.  
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6.2.2 PeptiENV with herpes simplex virus type 1  
 
According to tumour growth curves displayed in Figure 8, PeptiENV HSV-1 appears to 
inhibit tumour enlargement slightly more than CPP-SIINFEKL and HSV-1 only 
treatments. Injections were started on day 10, and on day 26 the average tumour volumes 
of PeptiENV and peptide only are 11 and 16 times larger than in the beginning, 
respectively. The difference is not unfortunately very significant. Instead, PeptiENV 
hinders tumour growth distinctly more than HSV-1 only. On day 22, mice treated with 
virus only has tumour sizes expanded on average to 12-fold while tumours injected with 
PeptiENV are approximately 6-fold on the same day.   
 
CPP-SIINFEKL peptide slows the growth slightly more than HSV-1 but the difference is 
not quite clear. Tumours injected with the peptide only reaches the same mean volume as 
the tumours in the HSV-1 group but slightly later, approximately between days 22–24. 
Tumours in the mock group grow clearly the fastest. On day 20, the mean tumour volume 
is 24 times larger than on day 10.  
 
 
Figure 8. Tumour growth in the PeptiENV HSV-1 animal experiment. Size of the tumours 
were measured every other day and they are presented as average relative volumes (%) 
with standard deviations.  
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Figure 9. Survival percentages of different treatment groups in PeptiENV HSV-1 
experiment presented as Kaplan-Meier curve.  
 
Survival times of the mice seems to be partly in line with the growth rates; small 
differences are observed between PeptiENV, HSV-1 and CPP-SIINFEKL only treatments 
(Figure 8; Figure 9).  Mice injected with PeptiENV stayed alive the longest, until day 38 
and 39, respectively, whereas all mice treated with mock had to be sacrificed until day 
32. As can be seen, the differences are not very significant.  
 
6.3 Immunological analysis of tumours 
 
The aim in these experiments was to determine the relative amount of tumour antigen 
SIINFEKL-specific CD8+ T cells in tumours collected from the animal experiments. The 
used method was extracellular staining of cell markers and flow cytometry.  
 
6.3.1 PeptiENV with vaccinia virus 
 
The proportional amounts of VACV- and tumour-specific CD8+ T cells are presented in 
Figure 10. Graph 10A shows that PeptiENV has the highest percentage of SIINFEKL-
specific CD8+ T cells in the analysed tumour tissue compared to the control treatments.  
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Figure 10. The relative amounts of tumour-specific (A) and VACV-specific (B) CD8+ T 
cells from total CD8+ population in tumours in the PeptiENV VACV experiment. The 
values of the columns are averages and displayed with standard deviations. Statistical 
analysis was performed with one-way ANOVA. P < 0.05*; P < 0.01**; ns. = not 
significant 
 
The difference is statistically significant (Figure 10A). VACV only and mock groups also 
generates few tumour-specific CD8+ T cells, but in CPP-SIINFEKL only treatment group 
specific CD8+ T cells were not detected.  According to the Figure 10B, the quantities of 
VACV-specific CD8+ T cells do not differ significantly between PeptiENV and VACV 
only groups.  
 
6.3.2 PeptiENV with herpes simplex type 1 
 
The results in Figure 11. suggest that tumours treated with PeptiENV HSV-1 have the 
biggest relative amount of SIINFEKL-specific CD8+ T cells compared to others. In turn, 
tumours injected with HSV-1 only does not seem induce tumour infiltration of 
SIINFEKL-specific CD8+ T cells at all. Mock and CPP-SIINFEKL only seem to elicit 
approximately the same amount of tumour-specific T cell-infiltration into the treated 
tumours.   
43 
 
 
Figure 11. The relative amounts of SIINFEKL-specific CD8+ T cells from total CD8+ T 
cell population in tumours in the PeptiENV HSV-1 experiment. The values of the 
columns are calculated averages shown with standard deviations.  
 
 
7 DISCUSSION 
 
The PeptiENV platform was studied with two different viruses, VACV and HSV-1, which 
were coated with MHC class I antigen epitope, SIINFEKL. Tumour growth was 
investigated in vivo by using a murine melanoma model, and treatments were given as 
intratumoural injections. Beside PeptiENV, control therapies used were virus only, 
peptide only and mock (complexation/injection medium only). The survival time of the 
mice was also observed. Subsequently, the tumour tissues of the treated mice were 
analysed with flow cytometry to obtain the relative amount of SIINFEKL-specific CD8+ 
T cells.   
 
7.1 Tumour growth and survival 
 
According to Figure 5. the PeptiENV VACV CPP hinders tumour growth most 
efficiently, and the difference between PeptiENV VACV CPP and VACV only is 
significant. This result is quite similar than in the study with PeptiCRAd by Capasso et 
al. (2016) which suggests that conjugating an oncolytic virus with tumour antigens has 
an advantage compared to treating with virus only. The PeptiENV VACV chol on the 
other hand, does not differ from VACV only considerably. Probably one reason for this 
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is that chol-SIINFEKL is not presented by APCs as strongly as CPP-SIINFEKL 
(Ylösmäki et al. submitted). As told in chapter 2.1.1, antigen presentation with MHC 
molecules is vital in activating the adaptive immune system and effector CD8+ and CD4+ 
T cells (Murphy 2012). In other words, the PeptiENV VACV chol might affect mainly 
through the oncolytic functions of the virus.  
 
Another interesting matter is that the growth rate of tumours treated with CPP- and chol-
SIINFEKL only is the highest, even greater than with medium (Figure 5). The peptides 
however, are tumour antigens thus, they could have vaccine-like effects that might have 
slowed the growth speed at least more than mock. Although, usually peptide-vaccines are 
administered with adjuvants that activates and matures dendritic cells (Butterfield 2015). 
Hence, delivering tumour peptides as such could cause immunological tolerance which 
might be a possible reason for CPP- and chol-SIINFEKL not showing any effect.  
 
The survivals of the mice are mostly in line with the tumour growth rates (Figure 5; Figure 
6; Figure 7). Mice treated with PeptiENV VACV CPP lived the longest compared to 
control treatments. Virus, peptides and mock in turn did not prolong the lifetime of the 
mice distinctively when compared to each other. As in preventing tumour growth, 
PeptiENV VACV chol did not increase survival time much from VACV only (Figure 5; 
Figure 7). Also, animals treated with chol- and CPP-SIINFEKL peptides only had the 
most rapid tumour growth and they had to be euthanized the soonest too (Figure 5; Figure 
6; Figure 7). The difference in these results compared to the growth curves is that VACV 
only does not seem to have any benefit compared to mock while it prevents tumour 
growth visibly more. The survival curves with these treatments are practically identical. 
May be that VACV hinders tumour enlargement only via oncolysis and is not able to 
induce a sufficient anti-tumour immunity, which is important for the clinical efficacy of 
oncolytic viruses (Kaufman et al. 2015). Hence, the survival might remain short even if 
tumour growth is prevented to some extent. In addition to the above said, the fact that 
PeptiENV VACV CPP prevents tumour enlargement and elongates survival the most 
indicates that PeptiENV therapy is beneficial over oncolytic treatment only. This 
observation is highly inciting.   
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The outcomes in the PeptiENV HSV-1 experiment resembles the results of the PeptiENV 
VACV study. The tumour growth rate is delayed by PeptiENV the most, and the 
difference compared to HSV-1 only is significant (Figure 8). The biggest variant is that 
CPP-SIINFEKL peptide averts the growth speed more than virus only, while in the 
PeptiENV VACV study the tumours expanded the most with peptide only treatments 
(Figure 5; Figure 8). Also, in this study, the difference in tumour growth rates between 
PeptiENV and peptide only is very small, whereas in the PeptiENV VACV experiment 
the PeptiENV VACV CPP clearly decreased tumour growth more than all control 
treatments. Furthermore, the survival of the mice in all treatment groups did not differ 
significantly from each other (Figure 9). Even though the tumour growth rate was 
obviously slower with PeptiENV than HSV-1 only, the survival times were virtually the 
same (Figure 8; Figure 9). Mice treated with CPP-SIINFEKL only had to be euthanized 
only slightly sooner than animals injected with PeptiENV and virus only (Figure 9). 
 
The Kaplan-Meier curves and the perception that HSV-1 alone hinders tumour 
enlargement more weakly than CPP-SIINFEKL are obscure (Figure 8; Figure 9). As seen 
in the PeptiENV VACV study, the peptide only treatments did not have any improving 
effect on tumour growth or survival (Figures 5; Figure 6; Figure 7). The used CPP-
SIINFEKL was exactly the same in both experiments therefore, the outcome in the 
PeptiENV HSV-1 study was expected to be similar with the PeptiENV VACV study. 
However, the tumour growth prevention with both HSV-1 only and PeptiENV compared 
to peptide only did not differ much, and survival is not prolonged in either groups (Figure 
8; Figure 9).  
 
The lack of efficiency of both virus only and PeptiENV treatments may be explained with 
the observation that HSV-1 does not replicate and cause oncolysis in the B16-OVA cells 
(Miller et al. 2001). An oncolytic virus destroys cancer cells and elicits anti-tumour 
immunity while single tumour peptides induce a very narrow immune response 
(Buonaguro et al. 2011; Kaufman et al. 2015). Therefore, in animal models in which the 
virus can replicate, an oncolytic virus would work better than single antigen epitope only, 
as seen in the PeptiENV VACV experiment. For this reason, the PeptiENV HSV-1 should 
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be investigated with more suitable model than B16-OVA in order to see bigger 
differences in the results.   
 
Improving the properties of the HSV-1 might also affect the outcome. The FDA approved 
T-VEC has several genetic modifications to enhance cancer specificity and 
immunogenicity, when the HSV-1 that was used in this research had only the firefly 
luciferase gene inserted (Nygårdas et al. 2013; Andtbacka et al. 2015).  It would be 
fascinating to see if different genetic changes of the HSV-1 would better the results. 
Presumably, the peptide conjugation should not affect the infectivity of the virus and thus, 
the efficiency of PeptiENV, according to the cell viability assay shown in section 6.1 
(Figure 4). Although, that option cannot be entirely ruled out based on this study only. 
Nonetheless, by altering the qualities of HSV-1 and using a more convenient animal 
model, upgrade of the results is achievable. In the end and despite the small differences, 
PeptiENV seems to prevent tumour growth most efficiently.  
 
7.2 Immunological analysis 
 
Considering Figure 10 in the PeptiENV VACV study, it is clear that tumours injected 
with PeptiENV has the largest relative amount of SIINFEKL-specific CD8+ T cells which 
points that PeptiENV induces a major anti-tumour immune response. VACV also 
generates a few tumour-specific T cells, probably via lysis of the tumour cells, but the 
amount is insignificant since medium only has almost the same value. Tumours treated 
with peptide only have so few SIINFEKL-specific T cells that they were not able to be 
detected which suggests that the peptide alone does not cause very strong immune 
response.  
 
When scrutinizing both Figures 10A and 10B, it can be seen that VACV only does elicit 
an immune response, but it is mainly against the virus. In the analysed tumours injected 
with virus only, the proportion of VACV-specific CD8+ T cells is higher than SIINFEKL-
specific T cells. This supports the presented possible argument, discussed in section 7.1, 
why the virus only did not improve the survival compared to other control treatments 
even though it hinders tumour growth more.  Important discovery is that the number of 
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virus-specific CD8+ T cells does not differ much between PeptiENV and VACV only 
treatments which points that fusing VACV with SIINFEKL peptides does not diminish 
the immune response against the virus (Figure 10A; Figure 10B). That is to say, the 
immune attack against VACV is similar whether using naked virus or PeptiENV but when 
using PeptiENV, the magnitude of tumour-specific T cell response increases. 
Consequently, the balance between anti-viral and anti-tumour immunity shifts towards 
the latter which is the aim in using oncolytic viruses and cancer vaccines (Butterfield 
2015; Kaufman et al. 2015). This observation most likely explains a big part of the 
efficacy of PeptiENV VACV CPP in both preventing tumour growth and elongating the 
survival of the treated mice (Figure 5; Figure 6). In other words, induced anti-tumour 
immunity is a dominant mechanism of action with PeptiENV.  
 
The relative amounts of SIINFEKL-specific CD8+ T cells in the PeptiENV HSV-1 
experiment are also positive. Tumours injected with PeptiENV seem to have distinctly 
more SIINFEKL-specific T cells than other tumours treated with control substances 
(Figure 11). Previously in chapter 7.1, the properties of the HSV-1 were discussed. The 
immunological analysis indicates that the virus is at least immunogenic since the 
PeptiENV elicits higher anti-tumour immune response than peptide only, which has the 
same amount of SIINFEKL-specific CD8+ T cells than mock (Figure 11). Although, the 
used B16-OVA murine model is not ideal, the missing of HSV-1 oncolysis and the 
displayed results point that the efficacy of PeptiENV HSV-1 is primarily derived from 
the induced anti-tumour immunity.   
 
Nevertheless, the absolute values are interesting. In the PeptiENV treated tumours, the 
amount of SIINFEKL-specific CD8+ T cells is approximately 30 % and thus extremely 
high (Figure 11). The numbers of control treatments are also quite large being between 
10–15 % except HSV-1 in which no tumour-specific CD8+ T cells are detected. The 
values do not seem realistic since in the PeptiENV VACV experiment the PeptiENV 
treatment has absolute percentage of SIINFEKL-specific T cells circa 12.5 %, which is 
the highest value in that study (Figure 10). In addition, the PeptiENV treated mice lived 
significantly longer which is not the case in the PeptiENV HSV-1 research (Figure 6; 
Figure 9). If the PeptiENV elicits this high immune response against the tumour, it could 
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be presumed that it would be seen as more efficient tumour growth prevention and 
elongated survival of the mice. 
  
On the other hand, the relative difference between the absolute values is not large (Figure 
11). Tumours treated with PeptiENV HSV-1 has two- to three-fold the amount of tumour-
specific CD8+ T cells compared to peptide only and mock whereas in the PeptiENV 
VACV experiment the difference between PeptiENV and other treatments is 
approximately 5-fold (Figure 10; Figure 11). Hence, the small differences are in line with 
the narrow variations in the tumour growth and the survival curves (Figure 8; Figure 9; 
Figure 11). It is possible that the zero-result of HSV-1 and the large absolute percentages 
derive from insufficient number of detectable events in the flow cytometry which leads 
to singular events having a big impact on the final values. Because of this, the results 
from the PeptiENV HSV-1 immunological analysis are mainly directional but still 
hopeful.  
 
To produce more accurate results in the measurements of the tumour-specific CD8+ T 
cells, the mice should be euthanized on a predestined day. The obtaining of the Kaplan-
Meier curves however, demands that the animals are sacrificed when a defined endpoint 
is reached. Studying the survival is important, but the disadvantage is that the euthanizing 
dates of the mice are distinctive. This can have an impact on the outcome since the 
animals may be in different stages considering the development of the immune response. 
The progression of the response is demonstrated in the study by Capasso et al. (2016) in 
which the relative amounts of SIINFEKL-specific CD8+ T cells varied depending on 
whether the mice were sacrificed early or later in the experiment. Because observing the 
survival is also crucial, an option would be executing an experiment with large enough 
number of mice to acquire both analyses. Of course, the ethical rules of animal 
experiments should also be noticed.  
 
Altogether, the results from both analyses are positive. PeptiENV clearly increases the 
amount of tumour-specific CD8+ T cells in the malignant tissue. This is extremely 
relevant since anti-tumour immunity is the basic objective in cancer immunotherapy, and 
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it has been discovered that in many cancers large number of tumour infiltrating CD8+ T 
cells is connected to favourable prognosis (Pagès et al. 2010; Papaioannou et al. 2016).  
 
7.3 General assessment 
 
As presented, the results in the PeptiENV VACV study are better than in the HSV-1 
experiment. One already discussed reason might be the insufficiency of the B16-OVA 
model for HSV-1. Instead, the model suits well for VACV because the virus is able to 
lyse the cells efficiently as seen in the cell viability assay shown in section 6.1 (Figure 4). 
This can explain the superiority of the PeptiENV VACV compared to PeptiENV HSV-1.  
Furthermore, as told in chapter 5.1, the HSV-1 used had very minimal genetic 
modifications, whereas the VACV had insertions for improving tumour cell specific 
replication and immunogenicity. These qualities are very important for oncolytic viruses, 
as discussed in chapter 3.3. By developing the properties of the HSV-1 further and 
choosing a better model, obtaining more significant results is feasible and thus, repetition 
of the animal study in the future is rational. Still, thorough in vitro investigations in 
advance are necessary to ensure the proper functioning of the virus.  
 
Although the outcomes in both experiments are quite satisfactory, especially in the 
PeptiENV VACV study, it has to be noted that the murine melanoma model (B16-OVA) 
used is artificial and does not represent an authentic situation. Utilizing preclinical models 
that are as close as possible to human physiology aids the prediction of how developed 
treatments will conduct in patients. Therefore, to verify the performance of the platform 
it would be reasonable to repeat the experiments with more realistic cancer models. For 
PeptiENV VACV study murine melanoma model B16-F10 would be appropriate since 
the cells express true melanoma antigens instead of artificial ones (Capasso et al. 2016). 
 
Hence the HSV-1 replicates poorly in the B16 cells, a completely different model could 
be tested. Workenhe et al. (2014) studied an oncolytic HSV-1 with murine HER-2/neu 
breast cancer cell line (TUBO) and demonstrated that the virus lyses the cells and 
replicates in them in vitro. The used HSV-1 shows also therapeutic efficacy in vivo by 
inhibiting the growth of implanted tumours in mice. In addition, it induces HER-2-
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specific anti-tumour immune response. The TUBO cell line might be a good model for 
PeptiENV HSV-1 experiment too. However, using an HSV-1 pentamer in the 
immunological analysis would be important because it would demonstrate the magnitude 
of the immune response against the virus, as in the PeptiENV VACV study, and verify 
the mode of action. Even more genuine approach for both experiments would be using 
humanized mice bearing human derived tumours. Moreover, because the tumour-antigen 
spectrum is very heterogenous, conjugating several kinds of TSAs onto the viral envelope 
might enhance the immune attack against the tumour tissue and improve results.  
 
It would also be interesting to integrate the prime-boost concept discussed in chapter 3.4 
with PeptiENV. In other words, different viruses would be utilized as the base of the 
platform, but the attached TSAs would remain the same.  As told, Bridle (2010) and Pol 
(2014) with their teams applied the concept to their studies and managed to considerably 
increase the amount of tumour-specific CD8+ T cells in the tumour and blood, 
respectively. Additionally, the survival time of the prime-boost treated mice prolonged 
significantly.  In the PeptiENV VACV animal experiment the same treatments were given 
as boosting treatments too thus, changing the viral backbone in the first or later treatments 
could improve the outcome even further. Because the results of the PeptiENV HSV-1 
experiment are relatively good, the HSV-1 may be suitable to be joined together with 
VACV in the future. Albeit, it was noted that using replicating viruses as primers might 
not work therefore, non-replicating version of PeptiCRAd could also be a valid option for 
priming (Bridle et al 2010; Pol et al. 2014). As discussed in section 3.4.1, the ability of it 
to induce a strong anti-tumour immune response has been addressed.  
 
Cancer immunotherapies are constantly used as compositions which is why examining 
the efficiency of PeptiENV with other treatments is subsequently essential (Butterfield 
2015; Papaioannou et al. 2016). For example, a very potential combination would be 
using PeptiENV with ICIs. The main purpose of PeptiENV is to induce a sufficient and 
specific anti-tumour immune response however, the platform does not have initial tools 
for overcoming the immunosuppressive tumour microenvironment. In turn, the ICIs are 
designed to block the T cell function impeding signals, but in order to work adequately 
they require a pre-existing anti-tumour T cell response (Obeid et al. 2015; Papaioannou 
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et al. 2016). The PeptiENV can provide that and thus, the two treatments could reinforce 
each other well. Furthermore, it is possible that PeptiENV would broaden the number of 
patients responding to ICI therapy.  
 
In addition to be an efficient and specific cancer treatment, the PeptiENV has been 
developed to function as a personalized immunotherapy platform. In other words, 
identified neoantigens of a patient would be attached to the envelope of the oncolytic 
virus. A major benefit is that the conjugation of peptides to the envelope is easier than 
modifying the viral genome which alleviates the use of variable antigens. The attachment 
of the SIINFEKL peptide has been successful, and the complexation process is quite 
simple as described in section 5.3 (Ylösmäki et al. submitted). A forthcoming challenge 
can rather perhaps be the production of the neoantigen epitopes. At present, it requires 
several steps before appropriate antigens are identified and can be transferred to a vaccine 
platform (Zhang et al. 2017). Individual tumour might contain thousands of mutations 
and all of them are not expressed. Hence, the neoantigen expression needs to be confirmed 
and also their binding to relevant MHC molecules. After, the epitopes must be further 
validated with in vitro studies. On the other hand, the technology has been dramatically 
improved and earlier this kind of neoantigen identification was extremely hard. 
Nevertheless, and considering the future, the manufacturing should be flexible and not 
too time-consuming or expensive. 
 
When viewing both animal experiments, tumour growths and immunological analyses, it 
is inciteful to see that the outcomes are quite similar despite the small differences 
presented. Especially PeptiENV VACV study showed that the combination of an 
oncolytic virus and TSAs is more efficient treatment than virus only. The HSV-1 
experiment did not produce as good results as the VACV, but the outcome is developable. 
Above all, the platform requires additional investigations for verifying the results 
displayed in this thesis and for further improvements.  
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8 CONCLUSION 
 
The PeptiENV platform was studied with VACV and HSV-1. Tumour-specific antigen 
epitope SIINFEKL was coated onto the envelopes of the viruses by using CPP or 
cholesterol anchor. By using VACV and CPP-SIINFEKL, it was shown that conjugation 
of the peptide does not decrease the infectivity of the virus. Additionally, in the first 
animal experiment, the PeptiENV VACV CPP is the best treatment since it prevents 
tumour growth remarkably more than virus, peptides or injection medium only. 
PeptiENV VACV CPP elicits significantly stronger tumour-specific immune response 
than control treatments as well. Conjugation of peptides does not reduce the immune 
response but in turn shifts it towards the tumour instead of the virus. In addition, 
PeptiENV VACV CPP clearly prolongs the survival of tumour bearing mice.  
 
In the second animal study, PeptiENV HSV-1 hinders tumour enlargement slightly more 
than virus and peptide only, and the difference is distinct when compared to HSV-1 only. 
However, there was no considerable variations in the survival times of the treated mice. 
PeptiENV HSV-1 also engenders a tumour-specific immune response, but the result is 
mainly directional. Currently, the PeptiENV platform seems to function with VACV 
more efficiently than with HSV-1. Nevertheless, further investigations are needed 
regarding both viruses. Overall, the results from both animal experiments are very 
encouraging and hence, the PeptiENV platform has remarkable potential in future cancer 
immunotherapy developments. 
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